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ADRIA L. BYKOWSKI. A novel method for the production of potentially therapeutic
human monoclonal antibodies in vitro. (Under the direction of Dr. Natalie Sutkowski).

We have developed a novel approach for the production of potentially therapeutic
human monoclonal antibodies in vitro. This method holds great promise for generating
therapeutic antibodies against infectious disease, cancer, and inflammation. The complex
nature of current methods for producing human monoclonal antibodies is a major
impediment to large scale passive transfer immunotherapy. Our novel technique utilizes
Epstein-Barr virus immortalized tonsil or peripheral blood B cells from healthy human
volunteers. These B cells are forced to undergo non-specific differentiation to become
mature IgG antibody producing plasma "like" cells that continuously proliferate in vitro.
U sing this method, millions of transformed B cells can be generated and screened for
production of antibodies of desired specificity. Optimization of EBV infection, reaching
nearly 100%, was achieved by combining viral concentration, using centrifugal
ultrafiltration with "spinfection". Thisallowed for transformation of the largest possible B
cell repertoire from human tonsil samples, a rich source of B cells. EBV immortalized
tonsil B cells were forced to undergo differentiation into IgG secreting plasma "like"
cells through addition of anti-Igm (Fab')2,

Interleukin (lL)-4 and IL-6 or anti-IgM

(Fab'h, soluble CD40L and BAFF once a week for three weeks. We hypothesized that
anti-IgM (Fab')2 would mimic antigen activation of the BCR and CD40L would mimic T
cell costimulation. ELISA analysis of supernatants from the immortalized cells indicated
that we efficiently induced immunoglobulin isotype class switching from IgM to IgG
after several weeks, and that the transformed B cells continued to secrete IgG for months
in vitro. Flow cytometry analysis revealed that IgG secreting immortalized B cells have a

XlI

differentiated surface expression phenotype that resembles plasma cells. We are currently
applying this differentiation method to produce therapeutic and diagnostic antibodies
against avian influenza virus hemagglutinin (H5 HA).

EBV immortalized tonsil and

peripheral blood B cells produced IgG antibodies specific for H5 HA. Overall, the results
indicate that differentiation of immortalized human B cells can be influenced in vitro,
with the ultimate purpose of exploiting their therapeutic potential.

XlII

Chapter 1: Background and Introduction
Human immune system
The immune system

IS

a collection of cells and secreted factors within an

organism that protects against infection by identifying and killing pathogens [1]. The
immune system protects the body from harmful substances by recognizing and
responding to antigens [2, 3]. Antigens are structural portions of molecules on the surface
of cells, viruses, fungi, or bacteria as well as non-living substances such as toxins,
chemicals, drugs, and foreign particles, which are recognized by the immune system.
Immune detection is complicated because pathogens adapt and evolve new ways to
successfully infect the host organism and evade immune detection, e.g. some viruses
have a very high mutation rate [2]. First-time exposure to pathogens like viruses and/or
bacteria sometimes triggers an immediate innate immune response, which is followed by
the robust adaptive response [3].
Microorganisms that successfully enter a host will immediately encounter the
innate immune system. Innate immune defenses are considered non-specific, meaning
these systems recognize and respond to pathogens in a general way, usually through
pattern recognition [5, 6]. The innate immune system does not confer long-lasting
immunity against a pathogen; however, it is an effective first line of organism defense
[4]. The innate response consists of chemical barriers, inflammation and specialized cells
that respond to infection [5]. Inflammation is the result of cytokines which are released
by injured or infected cells as well as T cells (part of the adaptive immune response) [1].
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These secreted chemicals raise the temperature in the affected area and recruit leukocytes
to the site of infection to promote removal of the pathogen as well as healing of any
damaged tissue [5].
Cytokines and complement are the major components of the innate immune
response. The complement system consists of over 20 proteins in the serum [5, 9, 10],
which work by attacking the surfaces of foreign cells. Complement can cause lysis of
foreign cells through different mechanisms including complement dependent cell
cytotoxicity (CDCC), and formation of the complement membrane attack complex (MAC
complex) [6].
The innate immune response utilizes many soluble and cellular forms of defense
to identify pathogens through pattern recognition, activating toll-like receptors (TLR) and
other receptors [12, 13]. Innate immunity can eliminate pathogens, by attacking them
through direct cellular contact, by engulfing and killing microorganisms or through
activating adaptive immune cells [7]. The innate immune system has an important role in
mediating the activation of the adaptive immune system by promoting presentation of
antigenic peptides and through secretion of cytokines [5].
The adaptive immune system allows for both a robust antigen-specific immune
response as well as immune memory, and is restricted to certain cell types. Memory is
defined by a subset of cells that are specific for a pathogen and respond quickly upon reexposure [8]. The adaptive immune response is specialized for individual pathogens [16,
17], and is maintained by "memory cells" (two subsets; Band T cells) [9]. If a pathogen
infects the body twice or more, specific memory cells quickly eliminate the invader.
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I

The adaptive immune response involves the activities of many cells known as
lymphocytes or white blood cells. B cells and T cells are the two major categories of
lymphocyte; they perform different tasks in the adaptive immune response [6, 9]. Both B
cells and T cells express receptors that recognize particular antigens (portions of
molecules that stimulate an immune response; there can be many antigens for one
pathogen). Lymphocyte activation results in memory responses [6, 10]. While they have
similar antigen receptors, Band T cells are very different. B cells are involved in the
humoral immune response (antibody production), whereas T cells are involved in cellmediated immune responses.
Cytotoxic T and helper T cells are major players in the adaptive immune
response, while natural killer T cells have a role in the innate. There are two major
subtypes of T cells involved in the adaptive immune response: cytotoxic (mainly CD8+)
and helper T (mainly CD4+) cells. Cytotoxic T cells cause direct lysis of pathogens and
infected cells, while helper T cells secrete cytokines and growth factors to amplify the
immune response [11]. Both types express T cell receptors (TCR) and recognize antigen
in the context of the major histocompatibility complex, (MHC) class I or class II
molecules [12]. MHC restriction means that T cells only recognize antigenic peptides
presented on MHC molecules [12]. MHC restricted cells cannot recognize antigens that
are unprocessed or not presented on MHC. Cytotoxic T cells mainly recognize antigenic
peptides expressed on Class I MHC molecules, which is expressed on all cells, and cause
direct lysis of infected targets [11,20,21] (Figure 1.1). Helper T cells mainly recognize
antigenic peptides presented on Class II MHC molecules, which are expressed on
macrophages, dendritic cells and B cells, resulting in secretion of cytokines and growth
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factors that help other immune cells to fight infection (Figure 1.1) [13]. The distinct
responses mounted by T cells reflect the different roles the two types of T cells play in
the adaptive immune response.

Interpreted from:
http://www.medscape.com/contentJ2003/00/45/20/452007/artcc452007.fig1.jpg

Figure 1.1. Helper T (CD4+) and cytotoxic T (CDS+) cell interactions with MHC and
antigenic peptide on an antigen presenting cell. Helper T cells are activated by
interaction with antigenic peptide in the context of MHC II. These activated cells then
secrete cytokines that enhance the immune response to the antigen. Cytotoxic T cells are
activated through interaction with antigenic peptide in the context of MHC I molecules.
The activation of these cells leads to direct killing of the cell presenting antigenic
peptides. Both types of T cells require a secondary costimulatory signal for activation,
which is received through CD28, and other costimulatory molecules.
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B cell immunology
Analogous to the T cell receptor on T cells, B cells express a specific
immunoglobulin (lg) on the cell surface which is known as the B cell receptor (BCR) [6].
NaIve mature B cells express both IgM and IgD molecules on the cell surface until
activation, at which point IgM becomes dominant. The B cell receptor on naIve cells is an
unmutated IgM antibody molecule, which is bound to the cell surface [6]. The B cell
receptor can recognize antigens on whole pathogens without any need for processing or
MHC presentation. Each B cell expresses a unique antibody, with estimates of
approximately 107 different antigen specificities possible [23, 24]. When B cells are
activated by specific antigens, the membrane bound immunoglobulin is converted to a
secreted form [14]. T cell help causes antigen activated B cells to differentiate. This
results in immunoglobulin isotype class switching, antibody secretion, and the production
of memory B cells. Ig isotype class switching

IS

a process that causes secreted

immunoglobulin changes from IgM to IgG, IgE or IgA [24, 25]. These secondary
immunoglobulin isotypes then undergo the process of somatic hypermutation of the
variable region, which results in affinity maturation i.e. secretion of antibodies that bind
the antigen better than their unmutated counterpart. The secreted antibodies can bind
antigens, and lead to complement activation, neutralization and/or engulfment of
pathogens [6].

Antibodies have two major portions, the constant region (Fc), which

changes during isotype class switching, and the variable region, which is responsible for
antigen binding.
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Antigen Presentation
B cells are key players in the adaptive immune response because they amplify the
immune response to pathogens and secrete antibodies to specific antigens. When antigen
interacts with the BCR on a naYve B cell, the antibody/antigen complex is internalized,
processed into peptides in the endosomes and presented on MHC class II molecules to
helper T cells [15]. The T cells provide secondary costimulatory signals that like CD40L,
the naYve B cells require for activation. T cells also secrete cytokines and growth factors,
that lead to B cell activation and maturation [6].

B cell differentiation
B cells can respond to T cell dependent antigens or T cell independent antigens
[16]. T cell dependent antigens require T cell help through costimulatory signals for B
cell activation [28, 29]. T cell independent antigens, like bacterial polysaccharides, can
directly induce B cells to produce antibodies in the absence of T cells [6, 17]. Once
activated, a blasting B cell undergoes cell division and begins to differentiate in the
specialized microenvironment of the germinal center in peripheral lymphoid organs [17].
Germinal centers are formed within a week of antigen stimulation. Antigen activated B
cells can follow two fates, either differentiation into plasma cells or into memory cells
[6]. Plasma cells are terminally differentiated B cells. They secrete high amounts of
monoclonal antibodies specific to the antigen that induced the B cell activation (Figure
1.2).

Memory B cells circulate and remain dormant until secondary encounter with

antigen, at which point they secrete affinity matured Ig [18]. In the germinal center Ig
isotype class switching occurs in antigen activated B cells in response to T cell secreted
cytokines [19]. Cytokines induce isotype class switching by activating the switch
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recombination sites that lie 5' to each C H gene [6]. Affinity maturation is the gradual
increase in the affinity of antibodies for a specific antigen, and is a consequence of
somatic hypermutation of the immunoglobulin genes [18]. B cells that have the highest
affinity for antigen are given survival signals during antigen presentation by follicular
dendritic cells, while lower affinity antibody producing cells do not recibed the survival
signals and are not expanded. This process is known as clonal selection [6]. The germinal
center B cells differentiate into to memory B cells or plasma cells, which exit the lymph
node and enter the periphery.
The B cell response to a pathogen during the first exposure is slow, taking more
than seven days to mount a robust response that clears the infection. During this time,
naive B cells differentiate into antibody secreting cells, resulting in antigen specific
clonal expansion, and memory is established (Figure 1.3) [6]. The memory B cells
provide long-lasting protection against re-infection with the same pathogen, and clear the
infection within a few days, when the pathogen is encountered again (Figure 1.3). The
activation and differentiation of a B cell results in immunoglobulin class switching from
IgM antibody, produced by naIve B cells, to higher affinity IgG, IgA or IgE antibody,
which is produced by immunized or memory B cells. Immunization results in rapid
production of affinity matured Ig. A slow primary response could be dangerous to the
host if the pathogen is lethal, making immunization important for human health.
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Figure 1.2. Antigen dependent B cell differentiation. Antigen binds to the B cell
receptor (purple) on naIve B cells. The antigen is then processed and presented to helper
T cells on MHC II molecules. The B cell blasts express activation markers like ICAM
and CD23. With T cell help, B cells differentiate into germinal center B cells where Ig
isotype class switching and affinity maturation take place. Memory B cells and plasma
cells are then released into the periphery where they secrete antigen-specific IgG
antibodies upon re-encountering the Ag.
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Figure 1.3. Specific memory by B cells increases immune response and shortens
reaction time to pathogens. The adaptive immune response to a primary pathogen
occurs slowly over several days and the antibody response is limited. However, upon reexposure, the memory cells mount a robust adaptive immune response immediately.

Terminally differentiated (plasma) B cells secrete antibodies that circulate in
blood, plasma and lymph, binding to specific antigens, pathogens, or virus infected cells
[35, 36] marking them for destruction through complement activation, and phagocytosis
(Figure 1.4). Antibodies can also neutralize pathogens directly, by binding to bacterial
toxins or by interfering with receptors that pathogens use to infect cells [6]. These
characteristics of antibodies make them effective against pathogens of many types.
Therefore, novel and cost effective ways of producing human monoclonal antibodies
could be of therapeutic value.
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Figure 1.4. Role of antibodies in the immune defense against tumors and pathogens.
Antibodies are produced by B lymphocytes in response to infections and cancer.
Antibodies have two

regions~

a constant region that is recognized by Fc receptors on

other immune cells, and a variable region that is specific for antigen.

Antibodies

neutralize pathogens and cause lysis of infected cells and tumor cells, making them very
desirable for vaccine use and anti-tumor therapy.
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Epstein - Barr virus (EBV)
More than 900/0 of the adult population is latently infected with the common
human herpesvirus EBV.

EBV is a double stranded DNA herpesvirus that encodes

approximately 100 genes, and is the causative agent of infectious mononucleosis, a selflimiting lymphoproliferative disease characterized by B cell expansion and extensive T
cell activation [20]. EBV preferentially infects resting B lymphocytes, both naIve and
memory B cell [21]. Cellular infection can be divided into lytic and latent stages. Lytic
infection results in viral replication, while viral latency is associated with lifelong chronic
infection [39, 40]. There are at least three forms of viral latency in B cells, which differ
in the expression profile of EBV latent genes, and the corresponding differentiation stage
of the infected B cell. The latency program comprise: (l)the growth program (also known
as latency III), (2) the default program (latency II) and (3) the memory program (latency
I) [22]. There are eight latent genes consisting of, EBV nuclear antigens (EBNAs) 1-6
and latent membrane proteins (LMPs) 1 and 2 [42-44].
Epstein-Barr virus is a tumor virus that is associated with several B cell
malignancies, which correlate with the different latency programs. EBV related posttransplant lymphoproliferative disease (PTLD) and AIDS related lymphomas arise during
the growth program of latency (latency III: EBNA 1-6, LMPI, and LMP2) and the B cells
resemble antigen activated B cells blasts. EBV related Hodgkin's lymphoma (HL)
derives from germinal center B cells that have undergone isotype class switching and
hypermutation, and express the default program of latency (latency II: EBNA 1, LMPI
and LMP2) [45].

EBV positive Burkitt's lymphoma (BL) derive from post-germinal

center or memory cells. They have characteristic chromosomal translocations between c-
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myc and the IgH enhancer, which are responsible for transformation; they express viral
latency I program (EBNAI only) (Figure 1.6). It is not known why some people develop
EBV associated B cell lymphomas, however tumors more commonly arise as a result of
.

.

ImmunosuppressIon.

EBV and B cell differentiation
Epstein-Barr virus is known to infect naive B cells, and the reigning theory on
infection is that it exploits the antigen dependant B cell differentiation pathway in order
to obtain access in the memory B cell compartment, the site of long-term viral persistence
[23]. EBV preferentially infects resting B cells by binding to CD21, and is internalized
by receptor-mediated endocytosis. Epstein-Barr virus has a unique ability to transform B
cells.

EBV infection of B cells in vitro, results in indefinite growth [46, 47] and

generation of lymphoblastoid cell lines (LCL).

These cells divide in the absence of

cytokines and antigen stimulation, which are normally required for proliferation (Figure
1.5). The proliferation is dependent upon the expression of 9 latent genes including six
nuclear proteins (EBNA 1, EBNA2, EBNA3a, EBNA3b, EBNA3c, EBNA-LP), three
latent membrane proteins (LMPl, LMP2a, LMP2b) and two small RNAs (EBERS) [24].
The infected cells resemble antigen activated B cell blasts. Lymphoblastoid cells are
growth selected and the growth is dependent upon EBNA2 and LMP 1. Cells that lose
EBNA2 expression subsequently stop dividing (Figure 1.5) [49-51].
In contrast, in vivo, EBV infected blasting B cells differentiate, and sequentially
loses nearly all viral gene expression. Once EBV gains access to the memory B cell
compartment, the virus is thought to evade detection by the immune system by residing
in resting cells that express limited viral genes (mainly EBNA 1, which is responsible for
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episomal maintenance) [40, 46, 52, 53]. Virus infected memory B cells reactivate when
they bind antigen, which triggers plasma cell differentiation. Lytic viral replication is
triggered by plasma cell specific gene expression [25]. The role that EBV plays in B cell
differentiation is unclear; however, viral gene expression at each stage has been
elucidated based upon the EBV tumors that arise.
Antigen dependent B cell differentiation occurs in the lymph node, and likely
requires antigen and T cell derived help in the form of cytokines and costimulation. It is
thought that the viral oncoproteins LMPI and LMP2 may partially supply B cell
differentiation signals leading to germinal center formation. LMPI and LMP2 are
functional viral homologs of constitutively active cellular CD40 and the B cell receptor,
respectively [55-58]. LMPI transcription factor NF-lCB, which promotes B cell growth
and differentiation, leading to uncontrolled B cell growth [57, 59]. Germinal center B
cells lose expression of EBNA2, which is a key transactivtor of other latent genes, and
express the default or latency II program of viral genes, EBNA1, LMPI and LMP2.
Further differentiation to memory B cells results in loss of LMP expression, and the exit
of latency I program cells (EBNAI only) from the lymph node into the periphery [26].
Memory cells are the long-term viral reservoir in which, the virus remains dormant, and
essentially hidden from the host immune system, until subsequent reactivation through
antigen/BCR interaction.' Activated memory cells become plasma cells that induce the
lytic cycle, leading to virus production, and de novo infection [54, 61, 62]. Disruption of
the tightly regulated surveillance of EBV infected cells can lead to EBV associated
lymphoproliferative disorders or lymphomas (Figure 1.6).
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Figure 1.5. Epstein-Barr virus infection of B cells differs in vitro and in vivo. In vitro
EBV causes B cells to blast, and maintains them in this state indefinitely. In vivo EBV
infects naive B cells and causes them to blast, like antigen. As the B cells differentiate
they lose the expression of the EBNAs, and express the LMPs, which mimic antigen
activation and T cell help. The B cells can differentiate into memory cells where EBV
persists or into plasma cells where viral replication occurs. Therefore, it is proposed that
EBV exploits the antigen dependent B cell differentiation pathway to gain access to the
memory B cell compartment.
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Monoclonal antibodies
Current monoclonal antibody (mAb) therapy: a vaccine alternative
Classic vaccinations work by activating the adaptive immune response and
eliciting a strong IgG antibody response. These vaccinations are based on the injection of
pathogen derived proteins in order to stimulate B cells to produce antibodies that bind to
the specific proteins [27]. The aim is to elicit an immune response that clears the
infection [11,64]. The antibody response to primary pathogen exposure slowly results in
formation of memory B cells [6]. The robust response elicited by vaccination is a means
of priming the immune system to attack the pathogen quickly upon subsequent exposure.
IgG are proteins made by B cells that circulate in the blood and are a major line of
defense [28]. Therapeutic monoclonal antibodies can confer passive protection against
specific pathogens to the recipient; however, no memory is made to the antigen.
Antibodies can be a safe and effective way to treat virulent viruses, tumors, and multidrug resistant bacterial strains. Several antibody therapies have been created for cancer
treatments, inflammation and autoimmune diseases [29]. One example is Rituximab, an
anti-CD20 antibody, effective against lymphomas; it acts through several mechanisms
including complement activation and caspase activation [66-70]. There is a strong need
to develop more therapeutic antibodies specific for tumor antigens for cancer treatment
and infectious pathogens to fight infection, that are both reliable and cost effective.
Avian influenza has caused three pandemics world wide in 1918, 1957 and 1968,
killing over 50 million people. There are no good vaccine for avian influenza and current
methods for producing influenza vaccines reI y on virus production in eggs, which is time
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consLuning and not suffIcient for producing enough vaccine for the entire population [7174].

Passive in1munization is an alternative to vaccination, [30] because hUlnan

1110noclonal antibodies can be adnlinistered before exposure to prevent illness. Therefore,
novel and fast methods for the production of human (IgG) monoclonal antibodies could be
considered as an alternative to classic vaccination for especially virulent pathogens.
Current methods for the creation of human monoclonal antibodies
Antibody therapy has proven efficacy in treating venonlOUS animal bites, certain
cancers and infectious diseases as a vaccine alternative [65]. In the 1970s, antigen specific
monoclonal antibodies were known to be therapeutically important but proved difficult to
produce, which made them a target for additional research to develop an easier method for
their production. At the time, it was known that mice could be exposed to antigens to
create antigen specific plasma B cells, but there was no way to isolate and expand the
plasma cells that produced the desired monoclonal antibodies. This made prolonged
monoclonal antibody production impossible. The first successful attempt to isolate and
expand plasma cells that produced antigen specific monoclonal antibodies was performed
in 1975 by Kohler and Milstein [31]. They demonstrated that mouse myeloma cells could
be fused with non-transformed spleen plasma cells from mice immunized against sheep red
blood cells (SRBC), resulting in continuously proliferating cells that produced antibodies
for several months in culture. These cells were fused by treatment with Sendai virus and
grown in media that promoted growth of myeloma cells and hybridized spleen-myeloma
cells. Kohler and Milstein found that the fusion of the two antibody-producing cells
resulted in the expression of Ig from both cells, indicating that allelic exclusion did not
occur in the resulting hybrid cell [31]. The Ig genes were randomly mixed in the hybrid but
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showed no changes to the rearranged genes encoding the constant or variable regions of
either cell. SRBC specific Sp-hybrid (spleen B cell and n1yelon1a hybrid) cells were
identified through plaque formation in SRBC-containing soft agar. Individual SRBC-lysing
hybrid clones were isolated and shown to retain expression of myelolna cell Ig as well the
SRBC-specific Ig in culture. The isolation demonstrated that antigen specific monoclonal
antibodies could be produced through cell fusion techniques [31]. The Sp-hybrid cells
resulted in direct plaques, and plaque formation was inhibited with the addition of anti-IgM
antibodies, which indicated that SRBC-specific IgM antibodies were primarily secreted by
the hybrid cells. This method allowed for the isolation of hybrid cell lines that produced
mouse antibodies directed against a specific antigen.
The hybridoma technology work of Kohler and Milstein demonstrated that specific
antibodies could be produced in culture, which led to several advances in antibody
research, technology and treatment. One of the resulting advances allowed for the
production of large quantities of monoclonal antibodies using both in vivo and in vitro
methods. The procedure yields cell lines capable of producing one type of antibody protein
for a long period. Hybridoma cells secreting monoclonal antibodies were produced by
fusing human lymphocyte-derived myeloma cells with primary antibody-producing plasma
cells from the spleen of an antigen challenged animal [76]. To facilitate the fusion,
myeloma cells were cultured with 8-azaguanine one week prior to fusion to ensure their
sensitivity to the hypoxanthine-aminopterin-thymidine (HAT) selection medium used for
hybridoma selection. 8-azaguanine ensured sensitivity by inhibiting the normal pathway for
nucleotide synthesis in the myeloma cells. Within the HAT medium, the inhibitor
aminopterin ensured that only fused hybridoma cells survived, by blocking the synthetic
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(de novo) path\vays through which nucleotides are nlade. In order for cells to survive, they
needed to bypass the defective nucleic acid synthesis pathway of the nlyelonla cells. Since
neither the nlyelonla nor the antibody-producing cells alone will grow in the selective
Inedia, only the fused hybrid cells survived [76]. These cells divided and secreted anilllalderived monoclonal antibodies indefinitely in culture [32]. While good for research, the
resulting animal-derived antibodies were incompatible with the human immune system
yielding ineffective therapies and serum sickness [77, 78].
There are several techniques for creating human and non-human antibodies of
certain specificity; however, with the change in technology comes change in procedures.
Early therapeutic antibodies were created using gene technology, a technique where
immunoglobulin variable (V) genes are amplified from hybridomas or B cells using
polymerase chain reaction (peR) [79].

These variable genes are then cloned into

expression vectors with soluble antibody fragments. The antibodies are then screened for
binding affinity.

This process is very time consuming and success rates for specific

variable regions are low [33]. Screening of variable genes was revolutionized when the
genes were expressed on phage. Complete antibody variable domains are displayed on the
surface of fd bacteriophage. These phage bind specifically to antigen and can be isolated
through affinity chromatography [24]. Affinity chromatography is time consuming, but
this technique is still being used.
Another method for human monoclonal antibody production is the use of
genetically engineered mice.

The major impediment to the development of murine

monoclonal antibodies (mAbs) for therapy in humans has been reducing their potential
immunogenicity. There have been several attempts to overcome this obstacle. One of
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these methods is XenoMouse technology [34]. These humanized mice retain the ease of
generating mAbs from a mouse without more cloning. XenoMouse strains carry portions
of the human immunoglobulin heavy chain (lgH) and light chain loci (JgK) among other
important human immunoglobulin genes. The transgenes were bred onto a strain of mice
with immunoglobulin deficiency. The XenoMouse mice are immunized with antigens of
interest, and mount an adaptive immune response, resulting in antigen-specific, fully
human immunoglobulin. These monoclonal antibodies from XenoMouse mice exhibit
therapeutic potential both in vitro and in vivo without serum sickness [34].
Human monoclonal antibodies have also been created from mouse antibodies
through substitution of the complementarity-determining regions (CDR). This technique
replaces mouse CDRs from the heavy-chain variable region of mouse antibody with the
corresponding CDRs of a human myeloma protein [35]. CDR replacement offers a
different way of constructing human monoclonal antibodies from corresponding mouse
monoclonal antibodies.
Recently, a new method for creating human monoclonal antibodies in vitro was
reported. This method utilizes Epstein-Barr virus (EBV) and peripheral blood from
volunteers that have been exposed to pathogens of interest. EBV was used to transform
human memory B cells from donors that have recovered from severe acute respiratory
syndrome coronavirus (SARS-CoV) infection and H5N 1 avian influenza virus [82, 83].
The obtained EBV infected memory B cells specific to the antigen of interest, which
secreted monoclonal antibodies that had the ability to neutralize pathogens. This method
demonstrates that EBV can be used to immortalize B cells and rapidly create human
monoclonal antibodies, which can neutralize pathogens. The limitation of that is that the
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B cells must come from a donor that has already cleared an infection. This method would
not work for some highly lethal pathogens because the infected people would die prior to
Ab production. Exposing a volunteer for antibody production is risky and un ethical.

Pitfalls of current monoclonal antibodies technologies
Current methods for the production of human monoclonal antibodies that have
been discussed are time consuming and labor intensive. To date, the most successful
approach for producing antibodies is the use of humanized mice that have been
genetically engineered to secrete human immunoglobulin [34]. However, the availability
of these mice has also hindered the mass production of antibodies, and they are typically
reserved for diseases like cancer. The methods that involve isolating memory B cells
from previously infected individuals are rapid and advantageous to the humanized mouse
model because the immune system of the volunteer has already done all of the work to
create human IgG specific to the antigen. However, this technology requires that the B
cells be isolated from a volunteer that has recovered from pathogen exposure. Prior
exposure and recovery from a pathogen leads to the problem of donor availability,
particularly for deadly pathogens such as Ebola [36]. These constraints on current
methods for the creation of monoclonal antibodies create a need for a novel technique of
antibody production that is both cost effective and can be scaled up quickly.
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Chapter 2: Rationale and Specific Aims
Antibodies are an important component of the immune response to pathogens and are
produced as a consequence of terminal B cell differentiation. Antibodies can neutralize
pathogens and cause lysis of infected cells and tumor cells through ADCC. These
qualities of antibodies make them desirable for pathogenic treatments and research needs.
In particular monoclonal antibody therapy has shown great promise in cancer
therapeutics (e.g. Rituximab) and is a very powerful alternative to conventional
vaccination. While polyclonal antibodies work well in some instances, monoclonal
antibodies are more desirable for therapeutic treatments [37]. However, the production of
human monoclonal antibodies is technologically complex, and existing protocols involve
their creation in humanized mice or by phage display technology, both with lengthy time
to production and high cost. Therefore, novel techniques for in vitro creation of human
mAbs may have therapeutic value.

A new method to create human monoclonal

antibodies in vitro involves immortalizing memory B cells with EBV.
Epstein-Barr virus is a common herpesvirus that is known to efficiently immortalize
B cells in vitro maintaining them indefinitely in a lymphoblastoid state called an LCL.
EBV causes na'ive B cells to blast, and LCLs are dependent upon the expression of 8 viral
genes; EBNAs 1-6 and LMP 1 and 2, However, in vivo, it is known that EBV persists
mainly in the memory B cell compartment, expressing only EBNA 1, where it can hide
from the immune system. It is also known that EBV preferentially infects naIve B cells,
and the current theory on infection is that it exploits the antigen activated B cell
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differentiation pathway to achieve access to the memory B cell compartment. Antigen
activated B cell differentiation is thought to be dependent upon T cell help, but has been
proposed that EBV encoded genes, LMPI and LMP2, may supply signals that force
differentiation. EBN A2 causes the infected B cell to blast, mimicking the first step of
antigen activated differentiation. Therefore, it may be feasible that an exogenous supply
of T cell derived cytokines and EBV encoded genes may force B cell differentiation in

vitro.
Since little is known about EBV+ B cell differentiation, it may be advantageous to
create an in vitro model to investigate this, while simultaneously working to create a
novel method for the production of human monoclonal antibodies. A good in vitro model
of EBY+ B cell differentiation might be a valuable tool for the study of Epstein-Barr
virus, B cell differentiation, EBV related cancer development and, also, antibody
production. With good primary EBV infection a large portion of the naIve B cell
repertoire could be immortalized. The addition of T cell derived cytokines and signaling
factors as well as BCR cross-linkage with anti-IgM (Fab'h to mimic antigen; could force

in vitro differentiation of EBY+ B cells. With efficient differentiation and classswitching, antibodies specific to many antigens could be created through non-specific B
cell differentiation. Should this technology prove feasible, it could circumvent many of
the current constraints on monoclonal antibody creation. Therefore, novel techniques for
creating human monoclonal antibodies using EBV may be of therapeutic value.

Hypothesis: Epstein-Barr virus infection will transform naIve B cells isolated from
healthy volunteers, and force the differentiation of B cells in vitro through the addition of
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exogenous
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Differentiated B cells that have undergone isotype class switching and secrete IgG
antibodies will be assayed for cross-reactivity with a selected antigen of interest, avian
influenza protein H5 hemagglutinin (HA).

Specific Aims
Specific Aim 1. Generation of tonsil and peripheral blood derived B cell repertoires using
Epstein-Barr virus and cytokines and signaling agents. This aim requiring two steps:
1. The optimization of EBV infection. Infection efficiency of Epstein-Barr virus
on B cells will be optimized through analyzing the effects of TLR ligand addition,
concentration and spinfection of EBV B95-8 and EBafV -GFP viral strains.
2. The induction of B cell differentiation and immunoglobulin isotype class
switching in EBV immortalized B cells. Exogenous T cell derived growth and
stimulation factors as well as B cell receptor cross linkage to mimic antigen will
be used to induce differentiation.

Specific Aim 2. The identification and isolation of in vitro differentiated B cell clones
producing human monoclonal antibodies (IgG) specific for avian influenza protein
H5HA.
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Chapter 3: Materials and Methods
Generation of tonsil and peripheral blood derived B cell repertoires.
Isolation and culture of tonsil B cells. To prepare B cells from tonsils, tonsil
tissue was placed inside a sterile Petri dish (VWR International, cat.# 25384-088)
containing 20-30 ml Dulbecco's phosphate buffered saline (DPBS, without CaCh or
MgCh , Gibco / Invitrogen, Grand Island, NY cat.#14190144) supplemented with Ix
Antibiotic-Antimycotic (Gibco / Invitrogen cat.#15240-062). The tissue was chopped and
minced with scalpels to approximately 1 mm 3 pieces. Additional lymphocytes were
released by gentle grinding of tonsil pieces between the frosted glass surfaces of two
sterile microscope slides (VWR cat.#12-550-34), and single cell preparation was made by
straining through 70 11m nylon strainer (BD Falcon, cat.# 352350, BD Biosciences, Two
Oak Park, Bedford, MA). This suspension was layered onto a Ficoll (Amersham
Biosciences cat.# 17 -1440-03, Uppsala, Sweden) cushion (35 ml sample over 15 ml
Ficoll) and resolved at 1500G for 20 min. The boundary layer containing mononuclear
cells was extracted, washed 2x with DPBS (1300G for 7 min), counted, and re-suspended
in DPBS.at 108 cells / ml. A highly enriched (>950/0) B-cell population was obtained with
the use of StemSep Negative Selection Human B-cell Enrichment Kit antibody cocktail
(cat.#14064A) and magnetic beads (cat.#19150) from StemCell Technologies Inc.,
Vancouver, Canada, according to manufacturer's instructions, with the following
modifications for use on a "The Big Easy" EasySep magnet (StemCell Tech. cat.#18001).
All steps were performed in a laminar flow biohazard hood at ambient temperature. The
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cell suspension was placed in a sterile round bottom 14 ml polypropylene tube (VWR cat
# 60818-689), mixed with an equal volume of the StemSep Negative Selection Human Bcell Enrichment Kit antibody cocktail, and incubated for 10 minutes. Then, a volume of
magnetic bead suspension equal to the antibody cocktail volume was added, followed by
10 minute incubation. The volume inside the tube was brought to 10 ml with DPBS and
the tube (minus the cap) was placed inside the magnet for 10 minutes, at which time the
contents of the tube (still inside the magnet) were gently decanted in a single pour into a
second sterile 14 ml tube. The original tube with non-B cells adhering to its walls was
removed from the magnet, and the second tube was inserted for 10 minute clean-up
incubation. The enriched B-cell suspension obtained after the first and second negative
selection steps was poured into a 15 ml Falcon tube, counted, washed with DPBS (1300G
for 7 min) and resuspended in an appropriate volume of complete RPMI media for in

vitro culture (generally 105 to 106 cells/ml in a 37°C, 5 % CO 2 tissue culture incubator.
Complete RPMI media contains RPMI 1640 (Gibco / Invitrogen cat.#11875-093) supplemented with 100/0 fetal bovine serum (FBS, HyClone cat.# SH30088.03,
lot.#AQC23460, Logan, Utah) -and 100 U/ml Penicillin / 100

~g/ml

Streptomycin

(cat.#15 140-122), 2 mM L-Glutamine (cat.# 25030-081),1 mM Sodium Pyruvate (cat.#
11360-070), 10 mM HEPES (cat.# 15630-080), 0.1 % 2-mercaptoethanol (cat.#
21985.023), and 0.1 % Falk's Cloning Cocktail, which consists of 50mM a-thioglycerol
(Sigma, cat.#M6145),

20~M

bathocuprionedisulfonic acid (Sigma, cat.#B 1125), 100mM

Na pyruvate (cat.# 11360-070), 1M HEPES pH 7.4 (cat.# 15630-080). L-glutamine,
Sodium Pyruvate, Penicillin/Streptomycin and HEPES were obtained from Gibco /
Invitrogen.
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Isolation and culture of peripheral blood B cells. To prepare B cells from
peripheral blood, venous blood (up to 180 ml) was drawn into 60 ml syringes containing
1 -5 ml citric acid -or heparin sulfate, which prevent coagulation, diluted with equal
volume of DPBS, layered onto a Ficoll cushion (35 ml of diluted sample over 15 ml
Ficoll) and resolved at 2000 rpm for 20 min. Serum (from upper layer) was collected and
stored in aliquots. The boundary layer containing mononuclear cells was extracted,
washed 2x with DPBS (1300G for 7 min), counted, and re-suspended in DPBS at 108
cells / ml. highly pure populations of B-cells are obtained with the use of StemSep
Negative Human B-cell Enrichment Kit (StemCell Technologies Inc.) as described above
for isolation of peripheral blood B-cells. Isolated B-cells were washed (1700 rpm for 7
min) and re-suspended at 10

5

-

106 cells per ml of complete RPMI media (described

above), and cultured in a 37°C, 5 % CO 2 tissue culture incubator.

EBV stock preparation. To prepare infectious Epstein-Barr virus (EBV) stocks,
B95-8 cells (obtained from David A. Thorley-Lawson), a marmoset lymphoblastoid cell
line (LCL) chronically infected with B95-8 strain EBV [38] or EBfaV -GFP
cells(described below), were cultured in complete RPMI media (described above) at a
cell density of approximately 105 cells / ml, in a 37°C, 5 % CO 2 tissue culture incubator.
EBfa V -GFP cells (a gift from Richard Longnecker) were derived from B95-8 cells,
where the EBV genome was modified by homologous recombination, deleting the
LMP2a gene and replacing it with enhanced green fluorescence protein (EGFP) (under
control of the CMV immediate/early promoter) as well as neomycin (neoR) resistance
gene [39]. These cells contain a mixture of EBfaV-GFP (LMP2-EGFP+) genomes and
wild-type B95-8 genomes.
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Approximately 140 ml of cell culture (containing either B95-8 EBV or
recombinant EBfaV -GFP) was induced to enter lytic virus production phase by treatnlent
with phorbol myristate acetate (10 ng/ml, Calbiochem, cat. #524400). After a four hour
incubation with PMA, the PMA was removed from the culture supernatant and replaced
with complete RPMImedia. The cells were cultured for 3 to 4 days until highly confluent,
at which point cells were removed by centrifugation (1300G for 7 min), and culture
supernatant was filtered through 150 ml Nalgene 0.45

~m

vacuum filter (Corning cat

#430320). Filtered supernatant was either flash-frozen in liquid nitrogen in 1.4 ml
aliquots for storage at -80°C in 1.5 ml Eppendorf tubes, or concentrated by ultrafiltration
as described below.
EBV concentration. Viral concentration was performed by loading the filtered
supernatant into two Centricon Plus-70 ] units (Millipore, Billerica, MA) and
concentrated according to manufacturer's instructions. The filter units were centrifuged
(2000G) for between 15 and 45 minutes (monitored each 15 minutes), until the minimal
retentate volume (approximately 0.5 ml per filtration unit) was achieved. The filtrate was
discarded, and virus-containing concentrates were re-suspended with complete RPMI up
to 14 ml (or 1/10 of the original culture supernatant volume). One ml aliquots were
transferred into cryovials, flash-frozen in liquid nitrogen, and transferred to -80°C freezer
for storage.
B cell infection by inoculation. B cells were resuspended at 106 to10 7 cells/ml in
complete RPMI media, and were mixed with an equal volume of filtered EBV
supernatant, then placed in a T -25 flask and incubated for 4 hours in a tissue culture
incubator at 37°C and 5% CO 2 . The culture volume was then adjusted by the addition of
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complete RPMI media, such that infected cells were resuspended for cell culture at the
desired concentration (generally 105 to 106 cells per ml), dispensed into multi-well plates
and transferred to a tissue culture incubator at 37°C and 5% CO 2 •
B cell infection by spinfection with concentrated EBV stocks. B cells were
resuspended at 105 cells/ml in complete RPMI media, and were mixed with an equal
volume of concentrated EBV and placed in a well of a 6 well tissue culture plate (Greiner
bio-one, cat #65760). The plate was then centrifuged at 900G for 1 hour at ambient
temperature, at which time infected cells were re-suspended in complete RPMI media at a
desired concentration (generally 106 to 107 cells per ml), dispensed into multi-well plates
and transferred to a tissue culture incubator at 37°C and 5% CO 2 .

Infection in the presence of TLR ligands. B cells were infected with B95-S
strain EBV as described above, with the addition of Toll-Like Receptor (TLR) ligands at
the time of the infection. The ligands were added at the following final concentrations:
Pam3CSK4 (0.5 J-lg/ml), zymosan (Zymoson)- (1 J-lg/ml), polyinosine, polycitadylic acid
poly I:C (25 J-lg/ml), lipopolysaccharide (LPS) (5 J-lg/ml), Imiquimod (1 J-lg/ml),
unmethylated CpG DNA (1 J-lg/ml). All TLR ligands (from In Vivogen Inc) were
generously donated by Dr. Mohamed Salem (MUSC).

Evaluation of B cell immortalization efficiency by lymphoblastoid cell
outgrowth. At 12 hours post-infection, B cells were counted and dispensed into wells of
96-well round bottom plates (Greiner cat#650 ISO) as a 2 fold dilution series, with each
consecutive row of wells containing half the number of cells found in the previous row.
The initial rows contained 50,000 cells per well, and final rows in the dilution series
contained 24 cells per well. Cells were incubated for 9 days in a tissue culture incubator
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at 37°C and 5% CO2 , at which point lymphoblastoid cell outgrowth was visible by
microscopy. Immortalization efficiency was estimated based upon the assumption that
lymphoblastoid cell proliferation resulted from EBV immortalization of at least one B
cell in the well. Thus, the efficiency was calculated from rows containing wells with the
lowest number of cells per well in which lymphoblastoid cell proliferation was
consistently observed by microscopy, and expressed as 1 immortalization event per
number of cells originally dispensed into the well.
Evaluation of EBV .. GFP infection efficiency of 293 cells. Because recombinant
EBV -GFP virus contains the EGFP gene encoding enhanced green fluorescence protein
in place of the latent membrane protein-2 (LMP2) gene, infection with the virus can be
measured by fluorescence microscopy or by flow cytometry as early as 24 hours postinfection. 293 cells were infected by inoculation or by spinfection as follows. Cells were
trypsinized, washed and resuspended in complete DMEM media, containing DMEM
(Mediatech cat.#10-013-CM), 10% Cosmic Calf serum (CCS, HyClone cat.#HS0087.03,
10t.#APE21241), Penicillin 100 Vlml, Streptomycin 100

~g/ml

(Gibco/Invitrogen,

cat.#15140-122)), at Ix106 cells I 1 ml per well into 6-well plates. 1 mlofEBfaV-GFP
virus stock, concentrated or un-concentrated, was added to the cells. Plates were either
incubated overnight for inoculation or centrifuged for 1 hour at 900G for spinfection.
Infection efficiency was determined 48 hours post-infection by visual inspection using
fluorescence microscopy.
Evaluation of EBfa V .. GFP infection efficiency of B cells. To quantitatively
evaluate B cell infection efficiency, tonsil B cells were dispensed into wells of a 96-well
5

plate at 2x 10 cells I 100 J.lI per well. TLR ligands were added to some of the wells at the
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concentrations previously described above, and cells were incubated for 4 hours at 37°C,
5% CO2 • Concentrated EBfa V -GFP virus stock (100 J.lI / well) was then added to all
wells and the cells were infected by spinfection as previously described. Infection
efficiency was analyzed by flow cytometry for EGFP+ cells 24 hours later.
Flow Cytometry analysis was performed using a Becton Dickinson FACSCalibur
instrument at the MUSC Flow Cytometry Facility, according to established methods.
Antibodies are listed in Table 2.
Induction of B cell differentiation. To determine their effect on B cell
differentiation during the immortalization process, cytokines and other signaling agents
were added to EBV infected B cells either immediately after infection, or 16 to 20 hours
after infection, and twice more at weekly intervals. All agents were diluted in complete
RPM I media and added to cells at the following final concentrations: recombinant human
interleukins (IL) IL-4, 0.2 ng/ml; IL-5, 0.2 ng/ml; IL-6, 0.1 ng/ml; IL-9, 0.2 ng/ml; IL-I0,
2.4 ng/ml; IL-13, 1 ng/ml; recombinant human interferon-a (IFN-a2a), 2,000 IU/ml;
recombinant human BAFF, 1 ng/ml; recombinant human soluble CD40L, 5 ng/ml; goat
anti-human IgM (Fab'h, 1.4

~g/mI.

IL-4 (cat. #200-04), IL-5 (cat. #200-05), IL-6 (cat.

#200-06), IL-9 (cat. #200-09), IL-IO (cat. #200-10), IL-13 (cat. #200-13), CD40L (cat.
#310-02) and BAFF (cat. #310-13) were obtained from PeproTech (Rocky Hill, NJ).
IFN-a2a (Roferon R -A) was from Roche Pharmaceuticals, and goat anti-human IgM
(Fab')2 (cat. #109-006-129) was from Jackson Immune Research Laboratories Inc.
Creation of immortalized B cell repertoires used in U5 hemagglutinin
binding studies. Tonsil or peripheral blood B cells were infected by spinfection with
concentrated B95-8 virus as described above. Immediately following spinfection, cells
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were resuspended in complete RPM1 media to which 1L-4 (0.2 ng/ml), 1L-6 (0.1 ng/ml),
BAFF (10 ng/ml), and goat anti-human 19M (Fab'h (1.62 Ilg/ml) (for three samples) or
CD40L (ng/mL),BAFF (10 ng/ml), and goat anti-human 19M (Fab')2 (1.62 Ilg/ml) (for
five samples) were added.

Measurement of human immunoglobulin IgM and IgG production by

ELISA. Culture supernatants (1 ml from each well of 24 well plates) were collected at
various time points beginning 1 week after infection and stored frozen at _20DC until
assay. Thawed supernatants,IOll1 per sample, or lOlll of standards consisting of purified
human 19G (Sigma-Aldrich cat. #12511) or 19M (cat. #18260), were mixed with 90111 of
binding buffer consisting of 100 mM Na2HP04, pH 9. Samples were then bound directly
to quadruplicate wells of Nunc 96-well EasyWash plates (Costar cat. #3369). All
samples were added to duplicate plates, one for detection of IgG, the other for detection
of IgM. Plates were incubated at room temperature for 1 hour, washed 4 times with wash
buffer consisting of PBST (80.0g N aCI, 11.6g N a2HP04, 2.0g KCI, 5ml Tween-20, pH
7.0 in lOL), and blocked with 2% BSA in wash buffer for 1 hour. Plate bound IgG and
IgM were detected using alkaline phosphatase (AP) coupled goat anti-human 19G or IgM
(Southern Biotech cat #2040-04 or 2020-04 respectively), lOOll1 per well diluted 1: 1,000
was added for 1 hour. After washing, AP conversion of colorimetric substrate pnitrophenyl phosphate disodium salt (PNPP, Peirce cat #37620) was detected by
measuring absorbance at OD405 using a Multiskan Spectrum plate reader
(ThermoLabsystems). Levels of human immunoglobulin in culture supernatant samples
were calculated following standard curve calibration of purified human IgG and IgM
standards using MultiSkan software.
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Sample collection for HA ELISA analysis. Culture supernatants were collected
once a week from tonsil and peripheral blood immortalized B cell cultures

(150~1

from

each well, replaced with fresh RPMI plus CD40L, BAFF and anti-human IgM). After
weeks 1 and 2, the supernatants were pooled by combining

25~1

of sample from each

well on a plate. For week 3, pooled supernatants were generated from individual rows on
each plate by combining

50~1

from each well in a specified row (A, B, C, etc).

Supernatant from the entire well was used for analysis when testing individual or pooled
dual wells. Once an individual well secreting anti-H5 HA IgG had been identified, cells
from that well were counted, and subcloned into at least four 96-well plates each
containing 1000, 100, 10 or 1 cell / well. After 2 weeks, sample collection and analysis
of supernatants from plates, then rows, then wells were repeated. The goal of the
subcloning strategy was to obtain H5 HA-reactive IgG from the wells initially plated with
no more than 1 cell per well.

H5 HA ELISA. Purified recombinant H5 hemagglutinin (HA) from H5N 1 avian
influenza strain A / Vietnam / 1203 / 2004 (Protein Sciences Corp) was diluted to 2
~g/ml
~l

in a high pH 100 mM sodium phosphate binding buffer (pH 9.0), dispensed at 50

per well into 96-well Eas-yWash plates (Costar cat. #3369), and allowed to bind

overnight. To help control for non-specific plate binding in each sample, an equal number
of wells received binding buffer only. Plates were then washed, and blocked with a
neutral pH 100 mM sodium phosphate buffer (pH 7.2) containing 2% BSA. Culture
supernatant from samples or controls 100~1 per well was added in triplicate. Controls
included serum from healthy human volunteers, diluted 1:500 with complete RPMI
media; purified human IgG (Sigma) and RituxanR (a humanized anti-CD20 IgG 1
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monoclonal antibody, Genentech, San Francisco, CA 94080, cat.# 50242-051-21, lot#
M70267) diluted to 5

~g/ml

in complete RPMI media. Subsequently the plate was

washed extensively. Next, alkaline phosphatase-coupled goat anti-human IgG diluted
1: 1,000 (Southern Biotech cat #2040-04) was added 100~1 per well, and incubated for 1
hour at ambient temperature, followed by detection with AP conversion of colorimetric
substrate consisting of p-nitrophenyl phosphate disodium salt (PNPP, Peirce cat #37620).
Absorbance was measured at 405 nm. Results were expressed as average 00405 values
± standard deviations (n=3) Background values resulting from non-specific sample

binding to uncoated wells (binding buffer only) was subtracted from the values obtained
from binding to H5 HA coated wells.
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Chapter 4: Results
Toll-Like Receptor (TLR) ligands and EBV concentration did not significantly
improve EBV infectivity. Traggiai et al. (2004) [82] reported that addition of at least
one TLR ligand (CpG) to cultured memory B cells could enhance EBV infection
efficiency. Since naIve B cells express several TLR [88] it was reasonable to assess the
effect of several TLR ligands on EBV infection of naIve B cells. Primary B cells were
incubated overnight with either Pam3 (Pam3Cys-Ser-(Lys)4) (O.5ug/mL), Zymosan
(1 ug/mL) ,

Poly

I:C

(polyinosinic-polycytidylic

acid)

(25ug/mL),

LPS

(lipopolysaccharide) (5ug/mL), Imiquimod (1 ug/mL) , CpG (1 Oug/mL), or in unaltered
media.

These are synthetic proteins that mimic antigens and each of these activates

different TLR and downstream signaling pathways in cells Pam3 (lipopeptides) [89]
binds TLR 2/1, Zymosan (boiled, trypsin-treated cell wall preparation of Saccharomyces
cerevisiae) binds TLR 2/6, Poly I:C (viral double stranded DNA mimic) binds TLR 3,

LPS (a microbial cell wall component) binds TLR 4 [89], Imiquimod (small-molecule
compound in the imidazoquinoline family that displays both antiviral and antitumor
effects) binds TLR 7, and CpG (hypomethylated DNA) binds TLR 9 [89]. We chose
these TLR ligands because they activate a wide range of TLR and give a good range of
acti vities. Then B cells were infected with unconcentrated EBV (B95-8) from preparation
1 or 2 (prep 1, prep 2). In figure 4.1A, Imiquimod, Pam3 and CpG addition, did improve
infection efficiency to nearly 1.5% in some cases.

But, the overall infectivity was

unacceptably low compared to control B cells not treated with TLR ligands (Figure
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4.1A). Viral preparation did have an effect on viral infectivity; this could be a result of
induction of stock cells (Figure 4.1A).
Since TLR ligands did not increase infection, viral concentration was pursued
because higher viral titer was achieved with retrovirus infection [40]. Viral concentration
can be achieved through several techniques. For our studies, we used ultra filtration
centrifugation to concentrate EBV. Concentrated or unconcentrated EBV was applied to
primary B cells, and infectivity was determined through blast formation. Our findings
indicate that concentration of EBV improved infection efficiency to nearly 5%, as
compared to un-concentrated virus from the same preparation which reached only 1%
infectivity (Figure 4.1B). Although TLR ligands had little effect on infectivity, viral stock
preparation varied in infectivity (Figure 4.1A and B). Viral concentration did increase
infectivity; however, it was not sufficient to immortalize a large portion of the naIve B
cell repertoire.
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Figure 4.1. Effect of TLR ligands and viral stock concentration on EBV infection
efficiency. Primary tonsil B cells (106 cells/mllwell) were seeded in 24-well plate and
infected with 1 ml of concentrated through ultra filtration centrifugation using Centricon
Plus-70 or un-concentrated B95-8 viral stocks from several different preparations, with
the addition of various TLR ligands as indicated; Pam3 (lipopeptides) [89] binds TLR
2/1, Zymosan (boiled, trypsin-treated cell wall preparation of Saccharomyces cerevisiae)
binds TLR 2/6, Poly I:C (viral double stranded DNA mimic) binds TLR 3, LPS (a
microbial cell wall component) binds TLR 4 [89], Imiquimod (small-molecule compound
in the imidazoquinoline family that displays both antiviral and antitumor effects) binds
TLR 7, and CpG (hypomethylated DNA) binds TLR 9 [89]. (see Materials and Methods).
After a 4 hr incubation, cells were dispensed into a 96-well plate using a 2-fold serial
dilutions, starting at 5x 104 cells/well and ending with 24 cells/well. LCLs were scored
visually by phase contrast microscopy 9 days post-infection. Percent (%) immortalization
efficiency was calculated as described in Materials and Methods. Means ± SD are shown
(n ~ 3). A. Effect of TLR ligands and viral preparation B. Effect of virus stock
concentration.
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The combination of viral concentration and "spinfection" increased in EBV
infectivity. "Spinfection" or "spinoculation" has been reported to enhance the infectivity
of other enveloped viruses, such as HIV [91, 92]. This technique involves combining
cells with viral stock, then centrifuging this combination at low speeds for one hour. To
evaluate concentration and "spinfection" techniques, Q293A cells, an adherent cell line,
were infected with a recombinant EBfaV -GFP virus; one of the latent EBV genes,
LMP2a, was replaced with the enhanced green fluorescent protein EGFP gene in this
virus [39]. Q293A cells were inoculated for 24 hours with concentrated preparations of
EBfa V -GFP or "spinfected" (900xG) with concentrated virus for 1 hour. In Figure 4.2A a
good portion of cells were infected with a 10-fold concentration of EBfaV -GFP.

In

Figure 4.2B, Q293A cells were treated with concentrated virus and "spinfected", the
combination increased infection efficiency over concentrated virus infection (Figure 4.2).
While "spinfection" and EBV concentration increased infection efficiency of an
established cell line, this technique still needed to be evaluated and infection efficiency
needed to be quantified on primary B cells, our primary target. Tonsil B cells were
"spinfected" with concentrated non-fluorescent B95-8 EBV or EBfaV-GFP and analyzed
by flow cytometry for GFP expression levels 24 hours post infection. Visual inspection
of the infection efficiency revealed that the combination of concentration and
"spinfection" was effective (Figure 4.3A). The infection efficiency was quantified by
flow cytometry 24 hours after infection, and compared with non-fluorescent B95-8
infected cells.

The combination of "spinfection" and concentration significantly

increased EBV infection of primary B cells. This method doubled the fluorescence of
virally infected B of which 45% of the cells were fluorescing above non-fluorescent
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infected cells, with an MFI of 61.9 (Figure 4.3B). An entire peak shift indicates that
nearly 100% of B cells are transuded using this method. This infection efficiency was a
great improvement over inoculation with un-concentrated virus (1-2%) and would be
sufficient for immortalizing a large portion of the B cell repertoire.
Our results for the optimization of EBV infection of B cells indicated that TLR
ligand stimulation and viral concentration did not increase infection efficiency adequately
for our needs. However, the combination of viral concentration and "spinfection"
dramatically increased infection of primary B cells.

A.
1 O-fold concentration

B.
concentration + spinfection

Figure 4.2. Effect of EBV concentration and spinfection on infection efficiency.
Q293A cells were trypsinized, counted and seeded at lxl06 cells/lml/well into 6-well
plates , and 1 ml of EBfa V -GFP concentrated stock, was added to the cells. Plates were A.
incubated overnight with concentrated EBfa V -GFP or B. cells were treated with
concentrated EBfa V -GFP centrifuged for 1 hour at 900G for spinfection. EGFP
fluorescence was detected with inverted microscope (lOX objective) 48 hr post-infection.
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Figure 4.3. Efficient infection of primary tonsil B cells with EBfaV ·GFP. B cells
(2xl05 cells/O.lml/well) were seeded into a well of 96-well plate, mixed with 0.1 ml of
10-fold concentrated EBfa V -GFP and "spinfected" or "spinoculated" at 900G for 1 hour.
Sin1ilar number of cells was infected with B9S-8 as a negative fluorescence control.
Infection was evaluated 24 hours later, either as A. visual evaluation of infection
efficiency with fluorescent microscope; or B. a flow cytometry analysis of infection. Gate
indi<;ates that 4S% of cells fluoresce above background with a mean fluorescence
intensity (MFI) shift from IS.1 +/- 6.2 for B9S-8 infected cells in grey to 61.9 +/- 22.6 for
EBfa V -GFP infected cells in green peak. The shift of the entire peak indicates nearly
1000/0 infection efficiency.
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T cell derived cytokines had varying effects on IgM and IgG secretion from
different samples. NaIve B cells are activated through interactions between the B cell
receptor (BCR) and specific antigen, which is helped by co-stimulatory signals from T
cells. B cell differentiation in vivo is dependent upon T cell help. Therefore, our lab
postulated that if we could supply both T cell derived growth and differentiation factors,
while cross-linking the BCR to mimic antigen, we could force EBV immortalized LCLs
to differentiate in vitro.
To test this postulate, we examined the effect that different cytokine combinations
had on differentiation specifically, as determined by IgG secretion. To examine the
specific effects that these cytokine combinations had on IgM and IgG secretion, primary
tonsil B cells were infected with B95-8 EBV, treated with cytokines or other agents listed
in Table 4.1 or the combinations of these outlined in Figure 4.4 and culture supernatant
was analyzed for IgM or IgG with ELISA. Figure 4.4 shows the secretion pattern of IgM
and IgG in three different samples, one week after infection and treatment. IgM was
primarily secreted in higher levels than IgG by all of the samples in most cytokine
treatments (Figure 4.4). Specifically, BAFF and CD40L and anti-IgM (Fab'h increased
IgM secretion over untreated cells (Figure 4.4). Alternatively, B cells treated with
cytokine combinations containing the anti-viral cytokine, IFN-a decreased total
immunoglobulin secretion after one week, when compared to untreated controls. Since a
similar pattern of expression was obtained from three different samples, cytokine
combinations had similar effects over several samples. Also, since the majority of
immunoglobulin secretion was IgM, a large portion of the tonsil B cells were nai·ve.
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Ta~le

4.1: Cytokines and other stimulating factors used to induce
class switching and differentiation of B cells
Name

Function

Working
Concentration

Anti-IgM
(Fab')2
IL-4

IL-5

IL-6
IL-9
IL-I0
'.

IL-13

Interferon
a (IFNa
2a)
BAFF

CD40L

Goat anti-human IgM (Fab')2; crosslinks IgM, mimics
specific antigen binding [41].
Cytokine produced by activated T cells and other
immune cells. Participates in several B-cell activation
processes: increased viability and proliferation rate,
enhanced secretion and surface expression
immunoglobulin [41].
Cytokine secreted by T cells; acts as a growth and
differentiation factor for both B cells and eosinophils;
promotes production of immunoglobulin [42].
Cytokine plays role in the final differentiation of B-cells
into Ig-secreting plasma cells [43].
Cytokine secreted by Th2 cells; stimulates cell
proliferation and growth [44].
Cytokine produced primarily by monocytes and
lymphocytes; enhances B cell survival, proliferation,
and antibody production[97].
Cytokine produced by activated T cells; involved in Bcell maturation, differentiation and Hodgkin's
...
development [45] .
Cytokine produced by stimulated T lymphocytes and
many other cell types; enhances MHC I and II
expression, activates a subset of antiviral genes [46].
The B lymphocyte activating factor; expressed by
monocytes, macrophages and DCs, plays a central role
in B lymphocyte development and activation [47].
A ligand for CD40; CD40 signaling induces B cell
differentiation and Ig hypermutation [48].
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Figure 4.4. IgG and IgM secretion profiles of B-cells from three tonsil samples
treated for 1 week with different signaling agents. Tonsil B cells from 3 separate
samples were prepared, inoculated with B95-8, seeded into 24-well plates, and treated
with indicated signaling agents and cytokine combinations as described in Materials and
Methods. Culture supernatants were collected. one week post-infection, and analyzed by
ELISA for IgG and IgM levels as described in Materials and Methods. Means ± SD of
samples and controls (n=4) are shown.
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Cytokines and signaling agents induce isotype class switching after several weeks in
culture. Cytokines and other signaling factors are necessary for B differentiation in vivo,

therefore we studied the effects of these signaling factors on EBV immortalized LCL.
Tonsil B cells were treated with cytokines and signaling agents for three weeks, and
supernatant was analyzed by ELISA after each week for up to 10 weeks. The tonsil B
cells from two samples received on different dates (Figure 4.5) were treated with the
same cytokine combinations for three weeks. These samples secreted primarily IgM after
one week (Figure 4.4). However, expression pattern of IgM and IgG changed with time

in vitro. After 8 to 10 weeks in culture the immunoglobulin expression pattern was
clearly different. Continued cytokine treatments with CD40L alone, or anti-IgM (Fab')2
in combination with IL-6, resulted in high levels of IgG secretion (Figure 4.5 A and B).
This increase in IgG was accompanied with a drop in IgM secretion. On the other hand, B
cells treated with anti-IgM (Fab'h and IL-4 secreted more IgM after several weeks,
however, it was only observed in one of the samples (Figure 4.5 A). The B cells in our
studies continued to secrete immunoglobulin at high levels for many weeks. These results
suggested that the LCLs had undergone immunoglobulin isotype class switching from
IgM to IgG through cytokine treatment.
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Figure 4.5. IgM and IgG expression profile after 8 weeks in culture of 2
representative samples following 3 weekly treatments with cytokines and signaling
agents. B cells from two tonsil samples were isolated, inoculated with B95-8 EBV,
seeded into 24-well plates, and treated with the indicated combinations of cytokines and
signaling agents as described in Materials and Methods. Cells were treated once a week
for the first 3 weeks, and the culture supernatants were collected weekly. Culture
supernatants collected on week 8 post-infection were analyzed by ELISA for IgG and
IgM levels as described in Materials and Methods. Two samples are shown here (A and
B), created from tonsils. Means ± SD of samples and controls (n=4) are shown. Signaling
agent combinations that contain anti-IgM (Fab')2 were highlighted in yellow and
combinations that promoted immunoglobulin isotype class switching are bracketed in
black.
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Cytokine treatments induced differentiation of primary B cells to early plasma like
B cells. Figure 4.5 demonstrated that, in general, cells treated with anti-IgM (Fab'h and
IL-6 increased IgG secretion and cells treated with anti-IgM (Fab'h and IL-4 increased
IgM secretion. Immortalized cells secreted high amounts of immunoglobulin for upwards
of 20 weeks (data not shown). These observations, when taken together, indicated that B
cell differentiation had occurred. In order to investigate whether naIve B cells had
become plasma cells in vitro, primary B cells and IgM and IgG secreting B LCLs were
stained for common B cell markers (Table 4.2). Figure 4.7 shows that uninfected primary
tonsil B cells were mostly naIve; all were CD 19, CD20 positive and large portions were
IgG positive. All had low expression of activation markers CD27 and CD30 (Figure 4.6
A). Conversely, IgM and IgG secreting cells were both similar to early plasma cells; all
were CD 19 positive and CD20 and IgD low and all had increased expression of the
activation markers CD30 and CD27 (Figure 4.6 B). IgG and IgM secreting cells differed
only in the expression of CD38, a terminal differentiation marker, which was upregulated on IgG secreting cells (Figure 4.6 B). These results confirmed that the cytokine
treated cells had undergone differentiation into immunoglobulin secreting plasma cells in
vitro and isotype class switching had been induced with the addition of anti-IgM (Fab'h

and IL-6.

Summary: To date, Epstein-Barr virus infection of primary B cells has been optimized to
achieve nearly 100% infection efficiency through viral concentration and "spinfection".
Cytokine combinations with CD40L alone or anti-IgM (Fab'h in combination with IL-6
or IL-9 and IL-13 increased activation of B cells and induced B cell differentiation to
yield high amounts of IgG secretion have been identified. The staining pattern of in vitro
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LCLs as compared to pnmary B cells indicated that cytokine treated LCLs have
differentiated and resemble early plasma stage cells that secreted IgG antibodies for
months in culture, an indication of in vitro differentiation.
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Figure 4.6. Immortalized B cells cultured with anti-IgM (Fab'h and IL-4 or IL-6
differentiated to early plasma "like" cells in vitro. Expression of indicated cell surface
markers (role of which is summarized in Table 4.2) was evaluated by flow cytometry (see
Materials and Methods) in A. primary tonsil B cells (green) and B. immortalized B cells
cultured for 19 weeks, with either anti-IgM (Fab')2 and IL-4, which secrete high IgM
levels (red) or anti-IgM (Fab'h and IL-6, which secrete high IgG levels (blue).
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Table 4.2. Cell determinants used to characterize B cell
populations by flow ·cytometry
Marker

Function

Expression

CD19

Assembles with the BCR in order to
decrease the threshold for antigen-specific
receptor-dependent stimulation
B cell surface molecule with a role in the
differentiation and development of B cells
into plasma cells
Member of the NGFITNF receptor
superfamily; present on germinal center Bcells. Soluble CD27 is produced by plasma
B cells

Pantropic B-cell marker

CD20

CD27

CD30

Transmembrane cytokine receptor
belonging to the TNF superfamily, has a
role in regulating the function,
differentiation an/or proliferation of
normal lymphoid cells

CD38

Functions in cell adhesion, signal
transduction and calcium signaling.

IgD

Immunoglobulin molecule with unknown
function
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Present on all mature B
lymphocytes, except plasma
cells
Marker for human
somatically mutated cells.
Found on both Band T
I ymphocytes upon cell
activation
Upregulated on postgerminal center cells;
present on Hodgkin's and
Reed-Sternberg cells and on
tumor cells of anaplastic
large cell
Expressed at multiple
stages; first appears on bone
marrow precursor cells but
is lost on mature
lymphocytes; it protects
germinal center cells from
apoptosis, but memory cells
exiting the germinal center
lack Cd38; present on
terminally differentiated B
cells
Present on mature naIve B
lymphocytes

Monoclonal antibody production
HSN! Hemagglutinin (HA) specific antibodies are found in sera of healthy humans.
The creation of plasma like cells in vitro, suggested that the process might be exploited
for the creation of human monoclonal antibodies specific for targets of interest, like avian
influenza. While most people have not been exposed to avian influenza, they have been
exposed to other closely related flu strains. Therefore it is reasonable to assume that
healthy individuals may have memory B cells that were stimulated by human influenza
viruses and which cross-react with the H5 HA protein of avian influenza. To confirm if
H5 HA cross-reactive IgG antibodies are present in the blood of healthy individuals,
serum was collected from five healthy volunteers (HS 1-5) and assayed by ELISA for
antibodies that bind to recombinant commercially obtained H5 HA. To detect these
antibodies in the serum, an ELISA using recombinant H5 HA was created.

H5 HA

specific binding was calculated by subtracting total binding to H5HA from background
binding (described in methods). Volunteers 1, 2, 3 and 5 (HS 1, 2, 3, 5) had varying
amounts of HA-specific IgG in the serum (Figure 4.7) with donors 3 and 5 having the
highest reactivity. However, Volunteer 4 (HS 4) had lower reactivity than our controls,
Rituxan (Rituximab) and purified total human IgG (sigma), indicating that this volunteer
lacked H5 HA cross-reactive IgG antibodies (Figure 4.7).

The detection of H5 HA-

specific IgG in the serum of healthy volunteers indicated that our ELISA was capable of
detecting H5 HA reactive IgG antibodies. Conversely, we could not use the ELISA to
detect IgM antibody binding because background binding was too high (data not shown).
The positive results for HA-specific IgG antibodies bolstered the hypothesis that IgG
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antibodies specific for H5 hemagglutinin of aVIan influenza could be created by
exploiting the B cell differentiation pathway.
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Figure 4.7. H5 HA-reactive antibodies are present in human sera from individuals
never exposed to H5Nl avian influenza. Samples or controls, rituxan and purified
human IgG, 0.1 ml per well were added in triplicate to ELISA plates previously coated
with recombinant H5 or to uncoated control wells. Rituxan and purified human IgG were
diluted to 5 mg/ml while human sera were diluted 1: 1000 in complete RPMI media.
Plates were washed, blocked and probed with anti-human IgG as described in the
methods . H5 HA coated plates were prepared by overnight incubation with recombinant
protein diluted to 2

~g/ml

in binding buffer, 0.1 ml per well. To help control for

background non-specific binding, each sample was added to an equal number of control
uncoated wells. Specific IgG binding to H5 HA was calculated by subtracting out the
values obtained from background binding to the control uncoated wells; mean absorbance
at OD 405 ± SD of samples and control are shown (blue bars).
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Immortalized B cell repertoires from PBM C secreted IgG antibodies specific for H5

HA. The ELISA results suggested that B cell clones of a given specificity could be
isolated from individuals that have not been exposed to H5N 1 avian influenza. To test
our immortalization and differentiation techniques, PBMC were extracted from Volunteer
5 (HS5=V5) who demonstrated high levels of H5 HA reactive antibodies in the serum. B
cells were cultured using two different cytokine/signaling agent combinations: (1) antiIgM (Fab'h, IL-4 and IL-6 (PBMC AI), (2) anti-IgM (Fab')2, CD40L and BAFF (PBMC
A2).

PBMC AI: B cells were isolated from PBMC of volunteer HS 5 and immortalized with
.EBV (Table 4.3). Cells were treated with anti-IgM (Fab')2, IL-4 and IL-6 to induce high
levels of immunoglobulin production, and plated in 3 96 well plates. Supernatant was
collected and pooled, and after one week there was little or no H5 HA-specific IgG
binding detected in the supernatant from any of the three plates, compared to human
serum controls (Figure 4.8). However, after two weeks of cytokine treatment H5 HAspecific IgG was detected in the supernatant from all three of the plates of B cells (Plate 1,
Plate 2 and Plate 3) (Figure 4.8). To determine the location of the reactive B cell clones
rows on reactive plates were pooled and assayed, then wells in reactive rows were pooled
and assayed. Several rows from each of the three plates contained cross-reactive B cells
(plate 1, row E; plate 2, rows C, D and E; and plate 3, row D) (Figure 4.9). Figure 4.11
indicates that the most cross-reactive B cells were located on plate 2, in row D, wells 11
and 12 (Figure 4.10). With further analysis of the supernatant the reactive B cell clones
were found to be on plate 2, in row D, well 11 (Figure 4.11); these clones were secreting
H5 HA-specific IgG at a level similar to our positive serum control (Figure 4.11). This
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well has since been subcloned, and identification of H5 HA-reactive clonal B cell
population is being pursued. A summary of the clonal isolation scheme and findings are
summarized in figure 4.12.
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Figure 4.8. Immortalized peripheral blood B cells from volunteer V -5 were
stimulated to produce IgG that binds H5 HA. EBV -immortalized B cells were
stimulated to produce IgG with anti-human IgM (Fab')2, IL-4, and IL-6 as described in
methods, and cultured in 3 96-well plates (10 4 cells per well). After week 1 (blue bars)
and week 2 (red bars),
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culture supernatants from all wells on each plate were

collected and pooled, then tested for H5 HA binding as described in the Materials and
Methods. Mean absorbance at OD 40S ± SD of samples and controls (n=3) are shown.

51

-o
In

2

&
Q)

o

1.S

c

CO

..c
o
rn
..c

1

~

o.s

~

<C

"C

c

..c
<C

0

J:

LO

J:

«

m u

0
==

0
==

'-

I

'-

0

==
'-

c w
0

==
'-

0

==
'-

Plate 1

E

u.

(!)

«

m u c

w u.

(!)

«

m u c

w u.

0
==

==
'-

0

==
'-

0

0
==

==
'-

0

0
==

0
==

==
'-

0

==
'-

'-

I

'-

0

==
'-

0

==
'-

0
==

'-

I

'-

'-

I I

Plate 2

0

==
'-

0
==

'-

0

Plate 3

0

==
'-

"
0

==
'-

I

::s

'(1)

tn

a.n
I

>

"en
c::

C'O

E

::s
.c::
~

::s

Q.

V-S Culture Supernatants

Figure 4.9. H5 HA specific IgG production in culture supernatant from individual
rows on plates containing immortalized B cells identified with binding activity, from
PBMC Al sample. 150111 of culture supernatants from all wells in each row of reactive
plates 1, 2 and 3 were pooled and assayed for H5 HA binding as described in the
Materials and Methods. Mean absorbance at OD 405 ± SD of samples and controls (n=3)
are shown. Rows with significant H5 HA binding (Plate 1, row E, Plate 2, rows C, D and
E, Plate 3, row D) were chosen for subsequent analysis.
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Figure 4.10. H5 HA specific IgG production in culture supernatant from paired
wells of rows on plates identified with binding activity, from PBMC Al sample.
Week 3 culture supernatant from pairs of adjacent wells in H5 HA reactive rows
identified in Figure 4.9 were pooled and assayed for H5 HA binding as described in the
Materials and Methods. Mean absorbance OD 405 ± SD of samples and controls (n=3) are
shown. Wells 11 and 12 on plate 2 row D were selected for individual analysis.
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PBMC Al sample. Culture supernatants from individual wells on plate 2, D 11 and D 12,
were assayed for H5 HA binding as described in Materials and Methods. Mean
absorbance OD 405 ± SD of samples and controls (n=3) are shown. H5 HA reactivity at a
level similar to that found in human serum controls was observed in well D 11; cells from
this well were chosen for subcloning.
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PBMC A1: Subcloning Scheme
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Figure 4.12. Subcloning strategy of H5 HA specific B cells found in plate 2 well Dll,
from PBMC AI. EBV-immortalized B cells from PBMC Al were stimulated to produce
IgG with IL-4, IL-6, BAFF and anti-human IgM (Fab')2 (see Materials and Methods),
4
and cultured in three 96-well plates (10 cells per well). H5 HA binding was determined

as described in the Materials and Methods. Culture supernatants from all wells on each
plate were collected (150!!1 per well), and

50~1

per well were pooled and assayed for H5

HA binding. All plates contained H5 HA-reactive IgG after two weeks and culture
supernatants from individual rows on these plates were pooled and assayed on week 3.
Plate 1, row E, Plate 2, rows C, D and E, and Plate 3, row D had significant H5 HA
binding. Culture supernatants from dual adjacent wells on each reactive row were
assayed, identifying wells 5 and 6 on Plate 1 and wells 11,12 on Plate 2, row D as
having, H5 HA binding. On week 5, reactive well D lIon Plate 2 was identified in a
similar manner, and cells from this well were subcloned by limiting dilution analysis in
96-well plates containing 1, 10, 100 or 1,000 cells per well. At weekly intervals
thereafter, culture supernatants from all wells on each plate were pooled and tested by
ELISA for H5 HA binding. Identification of a potentially clonal population secreting IgG
reactive with H5 HA was isolated from well Dl1 of the plate containing 1 ceJI per well
on week 8. The isolation strategy is summarized. Mean absorbance OD405 ± SD of
samples and controls (n=3) are shown.
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PBMC A2: B cells were isolated from PBMC of Volunteer HS 5 a second time and
infected with EBV (Table 4.3). Cells were immediately treated with cytokines anti-IgM
(Fab' )2, CD40L, and BAFF, which improved levels of IgO antibody production over the
combination used on PBMC A and B. Supernatant was collected, pooled and assayed for
H5 HA reactive IgG antibodies in 6., 96 well plates. After 4 weeks, three wells on two
plates (Plate 4 08, Plate 5 El and Plate 6 C2) contained cross-reactive IgG; the crossreactive wells were identified as outlined in figure 4.13. The three reactive wells have
been subcloned, and an H5 HA-reactive clonal population is being pursued. After
subcloning the binding of some of the antibodies was lost, this is demonstrated in Figure
4.13.

PBMC B: B cells were isolated from peripheral blood of Volunteer 6 and immortalized
with EBV (Table 4.3). The LCLs were treated with cytokines and signaling agents (antiIgM (Fab')2, IL-4 and IL-6) and plated in 3, 96 well plates. After three weeks of
treatment, no H5 HA -specific IgG antibodies were detected in the supernatant or serum
of Volunteer 6 (Figure 4.14). Analysis of this sample was discontinued due to a lack of
H5 HA cross-reactive IgG in the serum and supernatant of the LCLs.

Summary: Peripheral blood derived B cells from two volunteers were isolated and
immortalized with EBV. B cells that secreted H5 HA reactive IgG antibodies were
isolated from one of the volunteers., on two separate occasions (PBMC A 1 and A2),
which indicates that the results are reproducible. The cytokine and signaling agent
combinations were changed to improve isotype class switching and obtain more H5 HA
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reactive IgG secreting B cell clones in our samples. This change yielded more reactive
clones in PBMC A2 than in PBMC Al. The samples were isolated from the same
volunteer a little over a month apart. In contrast, B cells isolated from Volunteer 6 did not
yield any reactive clones and there was also no H5 HA-reactive IgG in the serum of the
individual. These results are summarized in Table 4.3.

Immortalized B cell repertoires from tonsils secreted IgG antibodies specific for H5

HA. While B cells that produced H5 HA-specific IgG were successfully isolated and
immortalized with EBV from peripheral blood (PBMC), in order to prove that we were
inducing differentiation of naIve B cells, we needed to obtain a naIve population thus we
used tonsil B cells from healthy children undergoing tonsillectomy. Cytokine/signaling
agents treatment was changed from anti-IgM (Fab'h, IL-4 and IL-6 for the first tonsil
(TNSL A) to anti-IgM (Fab')2, CD40L and BAFF for the rest (TNSL B thru E), because
the second combination was shown to selectively increase IgG secretion. We repeated the
experiments performed on the peripheral blood samples on 5 tonsil samples.
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PBMC A2: Subcloning Scheme
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Figure 4.13. Sub cloning strategy for isolation of H5 HA specific B cell clones from
PBMC A2. EBV immortalized B cells from PBMC A2 were stimulated to produce IgG
by treatment with anti-IgM (Fab'h, CD40L and BAFF, and cultured in six 96-well plates
4

(10 cells per well). H5 HA binding was determined as described in materials and

methods. Culture supernatants from all wells on each plate were collected
well), and

50~1

(150~1

per

per well were pooled and assayed for H5 HA binding. Plate 4, 5 and 6

were reactive with H5 HA, and culture supernatants from wells in each row on these
plates were pooled and assayed (week 2). Supernatants in dual adjacent wells from
reactive rows D and G on Plate 4, row E on Plate 5 and row C on Plate 6 were collected
and analyzed for H5 HA reactivity (week 3). The reactive wells G8 on Plate 4, El on
Plate 5 and row C3 on Plate 6 were subcloned by limiting dilution analysis into 96-well
plates containing 1, 10, 100 or 1,000 cells per well on week 4. Culture supernatants from
all wells on each plate were pooled and tested by ELISA for H5 HA reactivity,
identifying potential clonal populations of cells subcloned from Plate 4 and Plate 6 after
8-9 weeks. Mean absorbance OD405 ± SD of samples and controls (n=3) are shown.
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PBMC B: Subcloning Scheme

Week 1
Week 2
Week 3

Figure 4.14. Lack of H5 HA specific B cells in PBMC B. EBV immortalized B cells
from PBMC B were stimulated to produce IgG with IL-4, IL-6 and anti-IgM (Fab'h, and
cultured in three 96-well plates «104 cells per well). H5 HA binding was determined as
described in materials and methods. Culture supernatants from all wells on each plate
(150~ 1

per well) were collected, and

50~1

per well were pooled and assayed for H5 HA

binding. This was repeated for three consecutive weeks without significant detection of
H5 HA, at which point screening was discontinued. Mean absorbance OD 405 ± SD of
samples and controls (n=3) are shown.
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I
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CD40L, BAFF

J

I
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I
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I
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I

0

I

0

I
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CD40L, BAFF
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I
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I
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I

1

I

1

I
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CD40L, BAFF
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I

4

I

1

I
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I
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Positive

Subcloned well AIO from plate 3, screening and
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TNSL A: B cells were isolated from tonsil (Table 4.3), immortalized with EBV, treated
with (anti-IgM (Fab'h, IL-4 and IL-6) and cultured in 10, 96 well plates as described in
the methods. After one week, no H5 HA reactive IgG was detected. However, after two
weeks of cytokine treatments, H5 HA binding activity was detected on two (Plates 6 and
9) out of ten plates (Figure 4.15). After three weeks, two rows (C and F on Plate 9) were

identified as having H5 HA reactive IgG, unfortunately, this sample was lost to fungle
contamination contamination and analysis was discontinued (Figure 4.15). Despite the
loss, this sample demonstrated that IgG reactivity to our antigen of interest was possible
from naIve tonsil B cells.
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TNSL A: Subcloning Scheme

Week 1 plates

Week 2 rows and plates
Week 3 rows and plates

+/-

1-

+

1- 1- 1
* Contamination

Figure 4.15. H5 HA specific IgG identified in supernatant from TNSL A. EB V
imn10rtalized B cells from TNSL A were stin1ulated to produce IgG with IL-4, IL-6 and
anti- IgM (Fab' h, and cultured in ten 96-well plates

« 104 cells per well). Culture

supernatants from all wells on each plate (l50~ I per well) were collected, and 50~1 per
well were pooled and assayed for H5 HA binding. Week 1 analysis showed no reactivity,
while reactivity was detected on Plates 6 and 9 on week 2. Culture supernatants fr0l11 all
wells on individual rows on Plates 6 and 9 were pooled and assayed for H5 HA binding
as described in materials and methods. Rows C and F on Plate 9 were reactive; however,
the sample was lost due to fungal contan1ination after week 3, and screening was
discontinued. Mean absorbance 00 405 ± SO of san1ples and controls (n=3) are shown.
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TNSL B: B cells were isolated from tonsil (Table 4.3), immortalized with EBV, treated
with anti-IgM (Fab'h, CD40L and BAFF, to increase IgG antibody production and plated
in 10, 96 well plates. In the first week, H5 HA reactive IgG was detected on Plate 3
(Figure 4.16). However, after two weeks of analysis row D of Plate 3 was slightly
reactive, but no reactivity was recovered after four weeks. Therefore, sample analysis
was discontinued (Figure 4.16).
TNSL C:

B cells were isolated from tonsil (Table 4.3), immortalized with EBV,

stimulated with anti-IgM (Fab'h, CD40L and BAFF and plated in 10, 96 well plates.
After the first week, H5 HA reactive IgG was detected on plates 7, 8, 9 and 10 (Figure
4.17). However, after two weeks no H5 HA cross-reactive IgG antibodies were detected
on any of the plates and no reactivity was recovered after four weeks. Therefore, sample
analysis was discontinued (Figure 4.17).
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TNSL B: Subcloning Scheme

Week 1
Week 2 plates
and rows

1+ 1
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and wells
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Figure 4.16. Lack of HS HA specific IgG in supernatant from TNSL B. EBV
immortalized B cells from TNSL B were stimulated to produce IgG with CD40L, BAFF
and anti-IgM (Fab'h, and cultured in ten 96-well plates (2 x 105 cells per well). Culture
supernatants from all wells on each plate (150I-.d per well) were collected, and 50111 per
well were pooled and assayed for H5 HA binding. Week 1 analysis showed low level
reactivity on Plate 3, and culture supernatant from row D on Plate 3 was weakly reactive
on week 2; however, after weeks 3 and 4, no H5 HA reactivity could be detected on any
o~

the plates, and screening was thus discontinued. Mean absorbance OD 405 ± SD of

samples and controls (n=3) are shown.
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TNSL C: Subcloning Scheme

Week 1 plates

+/-

+/-

+/-

+/-

Week 2 plates
and rows
Week 3 plates
and wells

Figure 4.17. Lack of H5 HA specific IgG in culture supernatants derived from
immortalized from TNSL C B cells. EBV immortalized B cells from TNSL C were
stimulated to produce IgG with CD40L, BAFF and anti-IgM (Fab')2, and cultured in ten
96-well plates (>2 x 105 cells per well). One week later, culture supernatants from all
wells on each plate (150lll per well) were collected, and 50111 per well were pooled and
assayed for H5 HA binding. Significant H5 HA specific binding was not detected on any
plates. Mean absorbance OD 405 ± SD of samples and controls (n=3) are shown.
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TNSL D:

B cells were isolated from tonsil (Table 4.3), immortalized with EBV,

stimulated with anti-IgM (Fab'h, CD40L and BAFF and plated in 10, 96 well plates.
After one week, there was no detectable H5 HA reactive IgG in the culture supernatant
(Figure 4.18). However, after 2 weeks, H5 HA reactive IgG was identified on plates, 1, 8,
9 and 10 (Figure 4.19). Plate 10 exhibited H5 HA-reactivity as high as our human serum
controls; therefore, culture supernatants from paired wells were pooled immediately. The
other plates lost binding strength after the second week and were not pursued for cloning.
The reactive B cell clones were found on Plate 10, row G, wells 3 and 4, exhibiting
binding levels similar to human serum controls (Figure 4.20). B cells from both wells
were subcloned after three weeks, and the reactive well was identified as 04 (Figure
4.21). H5 HA binding was low after subcloning but binding increased with each week.
The identity of a

H5HA-reactive clonal population is currently being pursued. The

isolation scheme is summarized in Figure 4.23.
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Figure 4.18. Immortalized tonsil B cells (TNSL D) produce undetectable or very low
levels of IgG that specifically binds H5 HA after one week. EBV immortalized B cells
from TNSL D were stimulated to produce IgG with CD40L, BAFF and anti-IgM (Fab'h,
and cultured in ten 96-well plates (1.5 x 105 cells per well). H5 HA binding was
determined as described in materials and methods. One week later, culture supernatants
from all wells on each plate

(150~1

per well) were collected, and

50~1

per well were

pooled and assayed for H5 HA binding as described in the Materials and Methods
section. Significant H5 HA specific binding was not detected on any plates. Mean
absorbance level OD405 ± SD of samples and controls (n=3) are shown.
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Figure 4.19. Immortalized tonsil B cells on Plate 10 produced IgG that specifically
binds U5 UA after two weeks of culture, from TNSL D sample. Culture supernatants
from all wells on each plate of EBV immortalized B cells from TNSL D were pooled
(501l1 per well) after two weeks in culture and assayed for H5 HA binding. H5 HA
specific binding was detected on Plates 1,8,9 and 10, with highest reactivity on Plate 10.
Mean absorbance level OD405 ± SD of samples and controls (n=3) are shown.
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~L--J

controls

TNSL 0
Plate 10

Figure 4.20. H5 HA specific IgG production identified in culture supernatant from
paired adjacent wells on row G of Plate 10, from TNSL D sample. Cultured
supernatants from EBV immortalized B cells from TNSL D
collected from each well after 3 weeks of culture, and

50~1

(150~.d

per well) were

per sample from paired

adjacent wells on reactive Plate 10 were pooled and assayed for H5 HA binding as
described in materials and methods. All wells were pooled and assayed on reactive Plates
I, 8 and 9. Row G, wells 3 and 4 (green) had the highest H5 HA binding, similar to
human serum controls. Mean absorbance level OD 405 ± SD of samples and controls (n=3)
are shown.
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Figure 4.21. Identification of H5 HA .reactive IgG in Well G4 on Plate 10, from
TNSL D. Culture supernatants from EBV immortalized B cells from TNSL D sample
(50~.d

per well) on Plate 10, Row G, wells 3 and 4 were tested for H5 HA binding as

described in materials and methods. Row G, well 4 (green) had the highest H5 HA
binding and was selected for continued sub-cloning. Mean absorbance level OD405 ± SD
of samples and controls (n=3) are shown.
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TNSL 0: Subcloning Scheme
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Figure 4.22. Subcloning strategy for isolating H5 HA specific B cells from TNSL D.
EBV immortalized B cells from TNSL D were stimulated to produce IgG with CD40L,
BAFF and anti-IgM (Fab')2, and cultured in ten 96-well plates (1.5 x 105 cells per well).
One week later, culture supernatants from all wells on each plate
collected, and

50~1

(150~1

per well) were

per well were pooled and assayed for H5 HA binding as described in

materials and methods. After one week, no plates had H5 HA reactive IgG. However,
after two weeks Plates 1, 8, 9 and 10 exhibited reactivity, with Plate 10 exhibiting strong
reactivity. Culture supernatants from paired wells on each rowan Plate 10 were pooled
and assayed simultaneously with whole plate pools from Plates 1, 8 and 9. Paired wells 3
and 4 in Row G on Plate 10 produced H5 HA reactive IgG and production was
subsequently localized to well 04, which was subcloned by limiting dilution analysis into
96-well plates containing 1, 10, 100 or 1,000 cells per well. Isolation of a single cell
clonal population is currently ongoing. H5 HA reactivity could no longer be identified
from Plates 1, 8 and 9 after three weeks, at which point screening was discontinued.
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TNSL E:

B cells were isolated from tonsil (Table 4.2), immortalized with EBV,

stimulated with anti-IgM (Fab')2, CD40L and BAFF and plated in 4, 96 well plates.
After one week, plates 1 and 3 were weakly reactive to H5 HA (Figure 4.23). After two
weeks, plate 1, rows Band E and Plate 3, row A were identified as containing B cells that
secreted IgG reactive with H5 HA (Figure 4.24). Plate 1, row B wells 5 and 6, row E,
wells 3 and 4, 11 and 12; and plate 3 row A, wells 9 andIO were identified as IgG
reactive for H5 HA (Figure 4.25). Of these paired wells Plate I row Ewell 11 and plate
3, row A, well 10 contained reactive clones (Figure 4.26). Only Plate 3, row A, well 10
was subcloned because it had the strongest binding and gave us the best chance of and
finding a reactive clone. Reactivity was detected in 1000 cells/well after only five weeks
(Figure 4.27). The scheme for identifying reactive wells and subcloning reactive B cells
is outlined in figure 4. 27.

Summary: H5 HA reactive B cell clones have been isolated in two (TNSL D and E) out
of the five tonsil samples. A third tonsil sample exhibited early H5 HA reactivity, but the
sample was lost due to fungal contamination and no clones were recovered. The results
of the tonsil experiments are summarized in Table 4.3 Our results have indicated that our
approach for in vitro creation of human monoclonal antibodies from tonsil and peripheral
blood B cells against specific targets is feasible.
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Figure 4.23. Immortalized tonsil B cells produced undetectable or very low levels of
H5 HA reactive IgG after one week of culture, from TNSL E. EB V immortalized B
cells from TNSL E were stimulated to produce IgG with CD40L, BAFF and anti-IgM
(Fab')2, and cultured in four 96-well plates (105 cells per well). One week later, culture
supernatants from all wells on each plate (150IlI per well) were collected, and 50111 per
well were pooled and assayed for H5 HA binding as described in materials and methods.
Significant H5 HA specific binding was not detected on any plate above negative control
purified human IgG. Mean absorbance level OD405 ± SD of samples and controls (n=3)
are shown.
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U5 UA reactive IgG was detected in culture supernatants from

individual rows on Plates 1 and 3, from TNSL E. EBV immortalized B cells from
TNSL E were stimulated to produce IgG with CD40L, BAFF and anti-IgM (Fab'h, and
cultured in four 96-well plates (105 cells per well). Two weeks later, culture supernatants
from all wells on each plate (1501l1 per well) were collected and 50111 per well of each
was pooled from individual rows on plates 1 and 3, and then tested for H5 HA binding as
described in materials and methods. Supernatants from all wells on Plates 2 and 4 were
pooled and simultaneously assayed. Row A of Plate 3 and Rows E and B of Plate 1 had
significant levels of H5 HA reactive IgG, and were subjected to further analysis. Mean
absorbance level OD405 ± SD of samples and controls (n=3) are shown.
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Figure 4.25. H5 HA specific IgG production identified in culture supernatant from
pooled adjacent wells on Plates 3, 5 and 6, from TNSL E. Week 3 culture supernatants
from pairs of adjacent wells on Plate 1, rows Band E, and Plate 3, row A were pooled
and assayed for H5 HA binding activity as described in materials and methods. Plate 1
row B, wells 5 and 6; Plate 1 row E, wells 11 and 12 and 3 and 4; and Plate 3, row A,
wells 9 and 10 exhibited H5 HA reactive IgG production and were selected for individual
analysis. Mean absorbance OD405 ± SD of samples and controls (n=3) are shown.
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Figure 4.26. Identification of H5 HA specific IgG production in culture supernatant
from individual wells on reactive plates, from TNSL E. Week 4 culture supernatants
from individual wells B5 and B6, E3 and E4, Ell and El2 on Plate I wells and wells A9
and AIO on Plate 3, were assayed for H5 HA binding as described in materials and
methods. Strong H5 HA binding was observed from well AIO on Plate 3, which was
selected for subcloning. Mean absorbance levels at OD 405 ± SD of samples and controls
(n=3) are shown.
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Figure 4.27. Identification of H5 HA

specific IgG production was identified in

culture supernatant two weeks after sub cloning on plates containing 1,000 cells per
well, from TNSL E. Two weeks after subcloning immortalized B cells by limiting
dilution analysis, culture supernatants from each of the plates were pooled and assayed
for H5 HA binding as described in materials and methods. H5 HA binding was only
observed in supernatants from the 1,000 cells/well plate. Further subcloning analysis is
ongoing. Mean absorbance level at OD405 ± SD of samples and controls (n=3) are shown.
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Chapter 5: Discussion and Future Directions
A model of in vitro B cell differentiation was created using tonsil and PBMC
derived B cells, Epstein-Barr virus, exogenously supplied cytokines, recombinant
costimulatory molecule soluble CD40L, and an agent that induces BCR cross linkage
(anti-IgM (Fab')2). The aim of this model was to force B cell differentiation from mature
naYve B cells to plasma cell stage in the absence of T cells or other cellular interactions.
We have exploited this model to create human monoclonal antibodies in vitro for
therapeutic use. For creation of monoclonal antibodies, two major stages were required:
The first was optimization of EBV infection which required both viral concentration and
"spinfection". The second step was to induce immunoglobulin isotype class switching of
immortalized B cells using T cell derived cytokines and other signaling factors. These
steps were optimized to immortalize the largest portion of the naYve B cell repertoire
possible for the purpose of obtaining IgG antibodies specific to antigens of interest for
therapeutic use. Our in vitro B cell differentiation model can be applied to the study of B
cell differentiation, cancer, as well as Epstein-Barr virus research. In the current
application this model was exploited to create human monoclonal antibodies that
recognize H5 hemagglutinin (HA) of avian influenza.
Optimization of Epstein-Barr virus infection was achieved through the
application of several established methods for virus concentration. The first method
attempted was TLR ligands addition, which had been shown to improve EBV infection of
memory B cells [82]. TLR ligands mimic foreign antigens that are recognized by the
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innate immune system through binding to TLR on the surface of immune cells. Traggiai
et al. (2004) [82] demonstrated that the addition of

CpG~

an unmethylated portion of

DNA that activates TLR 4 and 9 [49], to their infection protocol increased EBV infection
efficiency of memory B cells to 30-100% [82]. Primary tonsil B cells are known to
express TLR 1,6,7,8,9 and 10, determined through northern blot analysis of primary B
cells, and high expression of TLR 9 and 10 on activated B cells [88]. Therefore, several
TLR ligands were analyzed for effect on EBV infection efficiency of tonsil B cells. TLR
ligands that bind a wide range of TLRs on B cells were assayed in our infection protocol:
Pam3, a synthetic lipoprotein mimics bacterial lipoproteins, binds TLR 2/1 [89],
Zymosan (Zymoson), from yeast cell extracts, binds TLR 2/;, Poly I:C, Polyinosinepolycytidylic acid, mimics double-stranded RNA of viruses, binds TLR 3; LPS,
lipopolysaccharide from bacteria, binds TLR 4 [89]; Imiquimod, imidaoquinoline amine
analogue to guanosine and antiviral, binds TLR 7; and epG, unmethylated DNA mimics
bacterial DNA, binds TLR 4 and 9 and activates B cells [89]. Each of these ligands has a
different structure and, mimics different antigen binding different TLRs on cells. In our
hands, the addition of Imiquimod, Pam3 and epG to our infection protocol doubled
infection efficiency to 2% (over 1% for untreated B cell infection) (Figure 4.1 A). The
increase observed with the addition of Imiquimod, Pam3 and epG was not unexpected
because these TLR ligands bind TLRs expressed on primary tonsil B cells; however, the
infection efficiency was low and varied with preparation (Figure 4.1).
Viral infection efficiency has also been shown to be effected by viral
concentration, a method that has been around for many years and has evolved with time.
Sucrose gradients were first used to concentrate herpes-simplex virus 1 through overlay
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of

VIrUS

on discontinuous gradients of 10%, 30% and 60% sucrose followed by

centrifugation. Alternativly, viral supernatant was added to five ml of 250/0 sucrose
followed by ultracentrifugation [50].

Similar methods for EBV were developed [51).

This resulted in purified and concentrated viral stock resulting in between 50-94%
infection. However, virus was lost at a high (>50%) rate through high speed
ultracentrifugation. Therefore, another method for EBV concentration was tried using T10 dextran, where virus was overlaid onto a 5-30% continuous gradient and centrifuged
at 76,000 xG for one hour [51]. Dextran gradients resulted in between 13 and 29%
infectivity. Both of these methods purify viruses from cellular contaminants, but they are
time consuming, expensive and require large quantities of virally infected cells, posing
bio-safety hazards. Thus we pursued other options. Retroviruses have been concentrated
by spinning viral supernatant at high speeds [40), however this will not work for less
hearty viruses like EBV. Concentration and purification of murine leukaemia virus was
achieved through ultrafiltration centrifugation, which increased infection efficiency
markedly [104-106). To apply this method EBV containing supernatant was centrifuged
over a column with a 100 Kb or larger cut-off and spun according to manufacturer's
directions. A large molecular weight cut off was thought to be the best, since EBY is
large compared to cellular contaminants and contaminants will be cleared quickly
without damaging the virus. The concentrated EBV was applied as described in methods
and increased our primary infection efficiency to 50/0 (over unconcentrated EBY at 1-2%)
(Figure 4.1 B).
"Spinoculation" or "spinfection" is a method that has been shown to increase
infection efficiency of several viruses [91, 92].
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In "spinfection" virus and cells are

combined and spun at low speeds (900-1200xG) for 1-2 hours at room temperature [91,
92]. This method has been shown to increase the infection efficiency of Cytomegalovirus
(CMV) and Human immunodeficiency virus (HIV) to nearly 100% and increased EBV
infection [92, 107-109] (personal communication with David Nadal).

We applied

concentrated EBfaV -GFP to primary tonsil B cells and spun them at 900xG for 1 hour.
After 24 hours we confirmed other reports, achieving near 100% infection efficiency of B
cells, seen as an entire peak shift in Figure 4.3 [52].

The mechanism of how

"spinfection" increased infection efficiency is a point of debate.

Some groups have

proposed that reversible virus binding to cells upon initial exposure was an underlying
mechanism [107, 110]. While other groups reported that "spinoculation" increases the
number of viruses binding to the cell surface by approximately 40% [52] resulting in
increased infection. Also, "spinfection" may alter the fluidics in the culture [52]. All of
these mechanisms are closely related and reasonable mechanisms for the observed viral
infection. Optimization of EBV infection of primary B cells was a necessary first step for
our novel method for the production of human monoclonal antibodies.
Having optimized EBV infection of B cells, the next step was to promote the
differentiation of the immortalized B cells in vitro. NaIve B cells are activated through
the interaction between the BCR and antigen as well as co-stimulatory signals from T
cells, such as CD40L and T cell derived cytokines. Current theory on EBV infection is
that the virus exploits the antigen dependent B cell differentiation pathway and EBV
genes may assist in this differentiation. Therefore, we postulated that we could force
EBV immortalized LCLs to differentiate if we could supply both T cell derived growth
factors as well as BCR cross-linkage to mimic antigen.
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To determine our starting point for differentiation, primary B lymphocytes, prior
to infection, were stained for common B cell markers. We found that the tonsil B cells
have a mostly naiVe B cell surface expression pattern: CD20 and CD 19 positive, which
are pan B cell markers, and CD30 and CD27 low, which are activation markers, and IgD
high, which is a naive B cell marker (Figure 4.6) [53]. This indicated that we were
starting with a mostly naIve B cell population.
We postulated that we would be able to track differentiation through ELISA
analysis of IgG and IgM secreted from the LCLs after treatment with the signaling
factors. Increased IgG would be a preliminary indicator that B cells have differentiated
and undergone Ig isotype class switching. It has been shown that IL-6 and BCR crosslinkage of primary B cells induced the loss of IgD, indicating that the cells had been
activated [54]. We confirmed this finding in our studies of EBV immortalized B cells of
two tonsil samples and PBMC Al (Figures 4.5, 4.6 and 4.12). Ligation of CD40 has also
been shown to induce terminal differentiation of naIve, memory and germinal center cells
in vitro [113-116]. We used soluble CD40L in the presence of BAFF, which plays an

important role in B cell development, survival, and immunoglobulin production [117], in
addition to anti-IgM (Fab'h which cross-links the BCR to force the differentiation of
EBV+ tonsil B cells. We confirmed these studies by demonstrating the appearance of IgG
antibodies after two weeks of treating two tonsil samples and one PBMC sample (TNSL
D and E, PBMC A2). Our results indicated that we could force B cell differentiation and
isotype class switching through the addition of anti-IgM (Fab')2 and either IL-6 (Figures
4.5, 4.6 and 4.8) or CD40L and BAFF and (PBMC A2, TNSL D and E, summarized in
Table 4.3).
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It has also been reported that IL-4 in combination with B cell receptor cross-

linkage and feeder cells causes primary B cell differentiation and Ig isotype class
switching from IgM to IgE and IgG [116, 118]. However, BCR cross-linkage and IL-4
treatment did not cause isotype class switching of EBV immortalized B cells. Instead, we
found that IL-4 and anti-IgM (Fab')2 increased IgM secretion (Figure 4.5). All of the
cytokine treatments tested sustained immunoglobulin secretion for many months in vitro,
which indicated that theses cells had differentiated to plasma like cells.
Differentiation of EBV immortalize B cells was confirmed through surface
staining of LCLs that preferentially secreted IgG (treated with anti-IgM (Fab'h and IL-6)
or IgM secreting cells (treated with anti-IgM and IL-4). As demonstrated in Figure 4.6,
primary tonsil B cells were initially mostly naIve: CDI9, CD20 and IgD positive, CD27
and CD30 negative (Figure 4.6). However, flow cytometry revealed that after treatments,
both cell populations resembled early plasma cells: CD2010, IgDlo, CD27 and CD30
positive [112, 119, 120). Plasma cells lose CD20, during maturation [55] and IgD is lost
after B cells have been exposed to antigen [54]. CD27 expression was induced by BCR
cross-linkage and maintained long-term by post-germinal center B cells [121-123];
CD30 expression is consistent with activated B cells [120]. Plasma cells secrete both IgM
and secondary Ig isotypes [56], which is consistent with our findings that EBV
immortalized, IgM secreting cells have a differentiated phenotype (Figure 4.6). The only
difference we saw by flow cytometry between IgM and IgG secreting cells was that the
IgG secreting cells expressed high levels of CD38, a common plasma cell and terminal
differentiation marker [53] while high IgM secreting LCLs had very little CD38 (Figure
4.6). Thus, our results indicated that the IgG secreting B cells had terminally
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differentiated.

Furthermore~

our results indicated that we have created a novel method for

inducing B cell differentiation of EBV immortalized cells in vitro by using exogenously
supplied 'cytokines, soluble CD40L and BCR cross-linkage.
Recently it has been shown that primary, naIve B cells isolated from PBMC or
cord blood, can be forced to differentiate and undergo isotype class switching through
BCR cross-linking in the presence of IL-21 and CD40 ligation [57]. At this time we have
not been able to reproduce this result in EBV immortalized B cells (data not shown),
indicating that EBV immortalized B cells may react differently to cytokine stimulation.
Huggins et al. (2007) found that culturing naIve (CD2710) primary B cells isolated from
PBMC in a 3 step system induced B cell differentiation to plasma cells [58]. The 3 step
program consists of: (I) CpG, IL-2, 10 and 15 for 4 days; (2) IL-2, IL-6, IL-I0 and IL-15
and anti-CD40 antibodies for the next 3 days; then (3) IL-6, IL-15, lPN-a, hepatocyte
growth factor, and hyaluronic acid for the last 3 days [58]. This method utilizes primary
B cells that are not immortalized with EBV and requires other means to activate the B
cells to begin differentiation. Another method involves stimulating primary B cells
isolated from PBMC with autologous B plasmacytoid dendritic cells (PDCs) followed by
treatment with CpG and BCR cross-linkage [127] to yield plasma cells. All of these
methods utilize primary B cells that are not immortalized with EBV.

One method

requires a feeder population to induce differentiation as well as exogenous cytokine and
TLR ligand addition.
Other methods to create plasma cells in vitro have utilized pnmary germinal
center B cells, cultured with CD40L expressing cells, and treated with IL-2 and IL-IO,
followed by removal of CD40L after one week [59]. Other methods involved activation
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of primary CD27+ memory B cells isolated from PBMC with CpG and IL-15 yielding
plasma cells that secreted antigen specific antibodies [114]. These methods differ from
our method because they rely on B cells that have already begun the differentiation
process, which can lead to less stringent activation requirements than naIve B cells. This
method also uses primary B cells that are not immortalized with EBV, which could alter
reacti vity as well.
It has also been found that culturing primary tonsil B cells with synoviocytes

induced plasma cell differentiation, and lead to high immunoglobulin expression [129].
NaIve and memory B cells isolated from PBMC that were cultured with CD32
transfected mouse fibroblasts coated with anti-CD40 and treated with and IL-4 followed
by IL-2, IL-3, and IL-I0 [60] differentiated to plasma cells in vitro. However, in this
system, memory B cells secreted IgG and naiVe B cells differentiated but did not undergo
isotype class switching to secrete IgG. This differed from our method, which has the
capability to force the differentiation and Ig isotype class switching to obtain IgG
antibodies.
Primary memory B cells isolated from PBMC and tonsils can be induced to
plasma cells through BCR cross-linkage and CD27 ligation with CD70. These cultures
also require the addition of IL-2, IL-4, and IL-I0 [130, 131]. Therefore, our method for
B cell differentiation is superior because we can induce differentiation of nai"ve B cells.
VH4-34 positive memory and naIve B cells cultured with irradiated CDl54-transfected
mouse fibroblasts and treated with CD70, IL-2 and IL-I0 underwent differentiation and
became antibody producing plasma cells [61]. This method required that a certain subset
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of B cells be used, limiting the use of this method for antibody production. Our method
was not restricted to a certain subset of B cells and could be applied to all naIve B cells.
Traggiai et al (2004) [82] has created a method for human monoclonal antibody
production through the immortalization of memory B cells from PBMC of SARS
recovered volunteers. The EBV infected memory B cells were first obtained from
mononuclear cells, and then treated with CpG to achieve IgG secreting plasma cells.
Simmons et al. (2007) [62] has performed a similar study in H5Nl recovered patients.
PBMC derived memory cells from avian influenza patients were isolated and
immortalized with EBV in the presence of CpG. Memory B cells secreting antigen
specific antibodies were isolated. Our method is similar to these methods because both
utilize EBV immortalized B cells to create plasma cells that will proliferate indefinitely

in vitro. Our method is different because we did not start with memory cells, but instead
forced B cell differentiation in vitro with external stimulation. Our method also does not
require that the B cells be isolated from a pathogen exposed individual, increasing the
availability of donors.
Our novel method for in vitro induction of B cell differentiation using EBV, BCR
cross-linkage, and soluble CD40L has been demonstrated to work in several tonsil B cell
samples (Figure 4.5, TNSL, A, D and E). We showed that we could induce production of
IgG antibodies specific for H5 hemagglutinin in tonsil B cells from healthy children not
known to be exposed to H5N 1 avian influenza. Our in vitro model of EBV+ B cell
differentiation can be applied in many research fields: Epstein-Barr virus infections, B
cell differentiation, and EBV positive B cell lymphogenesis (e.g. development of
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Burkitt's and Hodgkin's lymphoma), possibly leading to a new understanding and
possibly cancer therapies.
To test our hypothesis that we could exploit EBV immortalized B cell repertoires
for production of antibodies of therapeutic interest, we examined the serum of healthy
adult volunteers that had not been exposed to avian influenza, for IgG and IgM antibodies
for reactivity with H5 HA. It is possible that any healthy individual may have antibodies
that cross react with H5 HA. We found that 4 out of 5 volunteers (Figure 4.7) produced
IgG antibodies that bound H5 HA. We could not determine whether there was H5 HA
specific IgM because background IgM binding was so high that it interfered with the
ELISA analysis. The finding of H5 HA reactive IgG antibodies in the serum could be
interpreted to mean either that exposure to other flu strains might have resulted in an
immune response that was cross-reactive with avian influenza H5 HA [132]. It has been
found that immunity to influenza virus can influence later viral infection through altering
cytokine profiles[63]. The altered immune response might inhibit illness from other viral
infection or enhance or decrease mononuclear responses [63]. Thus, it has been shown
that heterologous immunity occurs between viruses resulting in altered protective
immunity [63]. For example, Clute et al (2005) [132]

found that some EBY+

mononucleosis patients have activated T cells specific for herpesviruses other than EBY,
indicating that closely related viruses may result in cross-reactive immune responses.
These findings allowed us to entertain the possibility that we could isolate B cells that
cross react with H5 HA from previously unexposed individuals.
The H5 HA ELISA that we developed was sensitive enough to detect IgG
antibodies, but not IgM antibodies in human serum. A H5N 1 avian influenza virus
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capture based ELISA has been developed USIng mouse monoclonal antibodies that
recognize H5 HA [64]. Monoclonal antibodies were bound to the plate then H5 HA was
added and human sample was layered on top, then detected with goat anti-human
antibodies. In comparison, the ELISA we developed had the capability to detect H5 HA
reactive IgG antibodies in serum and in cell supernatants in fewer steps. On the other
hand, the IgM ELISA we created was not able to detect H5 HA specific IgM due to high
background binding. This could happen because IgM is inherently sticky, meaning that
recognition of antigen is less stringent than IgG antibodies.

A capture based ELISA

where mouse anti-H5 HA is bound to the plate, then H5 HA is applied, followed by
sample supernatant and detection with a goat anti-human IgM antibody, might fix the
problem. The samples for the IgM ELISA could also be diluted or the percentage of BSA
could be increased in the block, to prevent non-specific binding.
H5 HA specific IgG producing B cells from healthy volunteers, were isolated
from both PBMC and tonsil samples. B cells were subjected to EBV infection and
differentiation. We were able to identify H5 HA IgG antibodies in the culture supernatant
from 1 (Figure 4.8 and 4.13) out of 2 healthy volunteers after two weeks of cytokine and
signaling agent treatments, possibly indicating that IgG producing B cells were not
originally in the culture and class switching had occurred. Identification of H5 HA
reactive IgG secreting B cells correlated with detection of IgG antibodies in the serum of
the individual. Serum concentration of H5 HA specific IgG from PBMC Al and A2, had
a high level of binding, while serum from PBMC B had no detectable binding. This could
also indicate that we immortalized memory B cells in the periphery from PBMC A that
cross-reacted with H5 HA.
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We repeated these experiments in tonsil (TNSL) samples to gain access to a larger
naIve B cell repertoire. Four tonsil samples (TNSL B, C, D and E) were treated with antiIgM (Fab')2, CD40L and BAFF, which resulted in the production of H5 HA reactive IgG
producing B cells that could be subcloned in 2 out of the 4 tonsil samples. A fifth tonsil
sample (TNSL A), treated with anti-IgM (Fab')2 and IL-4, also had H5 HA reactive IgG
(Figure 4.15), but was lost to fungal contamination and was not subcloned. For all
positive samples (TNSL A, D, E) H5 HA reactive IgG was detected at acceptable levels
only after two weeks of cytokine treatments (Figures 4.15, 4.22 and 4.28, Table 4.3),
consistent with induction of Ig isotype class switching between weeks 1 and 2. Thus,
overall we were able to identify H5 HA reactive IgG in approximately half of the TNSL
samples tested (3 out of 5), and H5 HA reactive B cells were subcloned from 2 out of 3.
Other studies on cross-reactivity of viral antibodies, have found that not all study
volunteers have EBV reactive antibodies that react with other herpesviruses [132].
Therefore, some volunteers will not have B cell repertoires that produce antibodies
specific for H5 HA.
Our method of non-specifically inducing B cell differentiation has allowed us to
isolate H5 HA specific IgG secreting B cell clones repeatedly in PBMC samples and two
TNSL samples (Table 4.3). On the other hand, we failed to recover H5 HA-reactive B
cells in two tonsil (TNSL B and C) samples that exhibited very low level H5 HA
reactivity after one week in culture, (Figure 4.16 and 4.17) but, by the second week, the
initial faint binding had been reduced and no reactivity was recovered. The disappearance
of the initial faint, positive signal could indicate two things; either our ELISA gave false
positive signals or that the reactive B cells died. Either way, testing of week one culture
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supernatants was unreliable, while positive results from week two supernatants were
consistently reliable. Even with the failure to get reactive clones in two samples, our
results indicate that we have created a novel approach for the production of human
monoclonal antibodies in vitro.
Our novel method of antibody creation is different is from all other human
monoclonal antibody production techniques. Technology has come a long way since the
first monoclonal antibodies were produced in animals. Those animal derived
monoclonals were not useful for therapeutics because they resulted in serum sickness [77,
78]. Phage display technology has sped up screening of antibodies [25] but, the resulting
antibodies were often of low affinity. Jones et a1. (1986) created a technique for the
productions of human monoclonal antibodies from mouse antibodies through substitution
of the complementarity-determining regions (CDR) [35] which elicits the serum sickness.
CDR replacement offered a different way of constructing human monoclonal antibodies
from corresponding mouse monoclonal antibodies. Our method is simpler and B cells
secreting antibodies of therapeutic interest can be identified by ELISA within a few
weeks of sample collection. Furthermore, the antibodies are entirely of human origin.
Another method for human monoclonal antibody production is the use of
XenoMouse technology [34] where mice express human immunoglobulin Ig genes
replacing the mouse Ig genes. Like CDR replacement, the humanized mice retain the ease
of generating mAbs from a mouse but avoid serum sickness and cloning. These
monoclonal antibodies from XenoMouse mice exhibit therapeutic potential both in vitro
and in vivo [34]. So far, humanized mice has proven to be a good approach for producing
antibodies; however, these mice are not available to the general public for mass
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production of antibodies. These constraints on current methods for the creation of
monoclonal antibodies create a need for a novel technique like ours that is relatively rapid
and cost effective.
Recently, a new method for creating human monoclonal antibodies in vitro has
been reported [82, 83]. This method utilizes Epstein-Barr virus (EBV) infection of
peripheral blood memory B cells from volunteers that have been exposed to and
recovered from pathogen infection [82, 83]. EBV was used to transform human memory
B cells to examine the B cell repertoire of donors that have recovered from SARS-CoV
and H5N 1 avian influenza virus infection [82, 83]. This method is limited because the B
cells must come from a donor that has already cleared an infection. This method would
not work for deadly pathogens like Ebola because donor availability becomes a problem,
and volunteer exposure is extremely hazardous and unethical [36]. Our method is
advantageous to these EBV immortalization methods because it does not require that the
donors were initially exposed to harmful pathogens.
A downfall of our method was that binding of H5 HA antibodies sometimes
decreased after subcloning, and in some cases the activity was lost. It has been noted in
the literature that genomic instability, chromosomal aberrations, aneuploidy and eventual
loss of cell function can result from EBV immortalization [135, 136]. Aneuploidy is a
state in which the wrong number of chromosomes impairs cellular function. This could
result in loss of IgG secretion and slowed cellular growth. We plan to side step this
problem through faster identification and screening of H5 HA reactive B cells. We will
then clone out the variable region from the isolated B cells and transfect myeloma cell
lines for production of H5 HA specific immunoglobulin.
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Future directions
We have identified B cell clones that secrete IgG that binds HS HA; we plan to
analyze, these cells for somatic hypermutation. Somatic hypermutation is indicative of
affinity maturation. B cell clones will be sequenced and compared to germ line sequences
from the same donor to determine if somatic hypermutation of the variable region has
occurred. We can also look by PCR, at B cells frozen at one week after immortalization
to compare the sequences.
We also plan to create more HS HA specific B cell clones through antigen
specific B cell differentiation. We will link H5 HA to beads, then when an antibody
recognizes and binds HS HA, the beads will cross-link the B cell receptor. This would
lead to antigen specific B cell differentiation. This method has successfully been used in

vitro to create antigen specific polyclonal antibody reaction [65]. This method could
potentially yield higher affinity HS HA-specific clones.
The antibody repertoire that we have created must be tested in in vitro
neutralization of HSN 1 and other flu strains on MDCK cells to determine if they have
therapeutic potential. These assays will be performed in the BSL 3 laboratory following
World Health Organization methods [138]. HSN 1 neutralizing antibodies will then be
examined for epitope mapping and variable regions of these antibodies will be sequenced
for future reference. Non-neutralizing antibodies might still be useful for diagnostic
purposes.
The identification of HS HA reactive antibodies from tonsil samples has many
implications for monoclonal antibody production. The first is that this technology can be
applied to create antibodies specific for many different antigens, including soluble tumor
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antigens and other viruses, not just avian influenza. Since our process is performed in
vitro using EBV immortalized human B cells, it has the capacity to be rapid and cost
effective. B cells that secrete antigen specific IgG can be frozen for long-term storage
and can later be grown up quickly as needed.
In summary, we have provided evidence that we can isolate, immortalize and
induce Ig isotype class switching of tonsil B cell and furthermore isolate B cells secreting
IgG of interest. We have also shown that this technology can be used to create human
monoclonal antibodies in vitro that are specific for H5 hemagglutinin (HA). We propose
that with further verification of this technology, it might be applied to the creation of
antibodies specific for other antigens of therapeutic interest.
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